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summary
Osteoporosis poses a significant public health issue. National Societies have developed Guidelines for the 
diagnosis and treatment of this disorder with an effort of adapting specific tools for risk assessment on the 
peculiar characteristics of a given population. The Italian Society for Osteoporosis, Mineral Metabolism and 
Bone Diseases (SIOMMMS) has recently revised the previously published Guidelines on the diagnosis, risk-
assessment, prevention and management of primary and secondary osteoporosis. The guidelines were first 
drafted by a working group and then approved by the board of SIOMMMS. Subsequently they received also the 
endorsement of other major Scientific Societies that deal with bone metabolic disease. These recommendations 
are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. 
When minimal evidence is available, recommendations are based on leading experts’ experience and opinion, 
and on good clinical practice. The osteoporosis prevention should be based on the elimination of specific risk 
factors. The use of drugs registered for the treatment of osteoporosis are recommended when the benefits 
overcome the risk, and this is the case only when the risk of fracture is rather high as measured with variables 
susceptible to pharmacological effect. DeFRA (FRAX® derived fracture risk assessment) is recognized as a 
useful tool for easily estimate the long-term fracture risk. Several secondary forms of osteoporosis require a 
specific diagnostic and therapeutic management.
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n	 INTRODUCTION  
 AND METHODOLOGY
Methods
This document covers the guidelines for the diagnosis and management of both 
primary (postmenopausal and senile) and 
secondary osteoporosis. The recommenda-
tions were developed using a demonstrable 
and reproducible process for the evaluation 
of the bibliographic references, and result 
from a weighted evaluation of the level of 
evidence (Tables I-IV).
The recommendations were first prepared 
by a dedicated Committee and then re-
viewed and shared with a large number 
of representatives of general practitioners 
and representatives of various medical 
specialties involved in the diagnosis and 
prevention of osteoporosis, as well as 
with epidemiologists and health econom-
ics experts. 
Level of evidence
Criteria used to assign a level  
of evidence to articles
• Studies of treatment and intervention
In recent years, registration studies of con-
siderable size that included more subjects 
than previous meta-analyses have been 
conducted. For this reason, it was decided 
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not to assign a higher level of evidence to 
meta-analyses of independent trials.
The levels of evidence described above 
will be integrated with individual notes 
taking into account post-hoc analyses that, 
despite having limitations, were considered 
to be particularly convincing.
deFINItIoN
Osteoporosis is a systemic skeletal disor-
der characterized by decreased bone mass 
and qualitative alterations (macro- and 
micro-architecture, bone material proper-
ties) associated with increased fracture 
risk. Primary osteoporosis is defined as 
osteoporosis occurring after menopause 
(postmenopausal osteoporosis) or with ad-
vancing age (senile osteoporosis). Second-
ary osteoporosis is caused by a number of 
disorders and drugs. 
Bone densitometry allows quite accurate 
and precise measurement of bone mass, 
particularly its mineral density [bone min-
eral density (BMD)] in g/cm2 of projected 
bone area. BMD accounts for 60 to 80% of 
bone mechanical resistance.
According to the World Health Organiza-
tion (WHO), a densitometric diagnosis 
of osteoporosis should be based on BMD 
measured by dual-energy x-ray absorp-
tiometry (DXA), compared to the mean 
BMD in young normal adults of the same 
sex (peak bone mass). The unit of mea-
surement is the standard deviation (SD) 
above or below the mean peak bone mass 
(T-score). It has been reported that fracture 
risk begins to increase exponentially at a T-
score <-2.5 SD, which has been established 
by the WHO as the cut-off for diagnosing 
osteoporosis. Bone densitometry is there-
fore the diagnostic test for osteoporosis 
and fracture risk assessment, just as blood 
pressure measurement is used to diagnose 
arterial hypertension and assess the risk of 
stroke. 
According to the WHO, the following defi-
nitions should be used to interpret BMD 
measurement: 
1) Normal BMD is defined as a T-score 
between +2.5 and –1 (the patient’s 
BMD is between 2.5 SD above and 1 
Table I - Studies of diagnosis.
Level of 
evidence Criteria
1 i. Independent interpretation of test results
ii. Independent interpretation of the diagnostic standard
iii. Selection of individuals suspected (but not proven) 
to have the disease
iv. Reproducible description of the test and the diagnostic standard 
v. At least 50 individuals with and 50 individuals without the disease 
2 Meets 4 of the Level 1 criteria
3 Meets 3 of the Level 1 criteria
4 Meets 1 or 2 of the Level 1 criteria
Table II - Studies of treatment and intervention.
Level of 
evidence Criteria 
1 Systematic overview of meta-analysis of randomised controlled trials
2 Randomised controlled trial that does not meet Level 1 criteria
3 Non-randomised controlled trial or cohort study
Table III - Studies of prognosis.
Level of 
evidence Criteria
1 i. Inception cohort of patients with the condition of interest, but free of the outcome of interest
ii. Reproducible inclusion and exclusion criteria
iii. Follow-up of at least 80% of participants
iv. Statistical adjustment for confounders
v. Reproducible description of the outcome measures
2 Meets criterion i and 3 of the 4 of the Level 1 criteria
3 Meets criterion i and 2 of the 4 of the Level 1 criteria
4 Meets criterion i and 1 of the 4 of the Level 1 criteria
Table IV - Grades of recommendation for clinical 
practice guidelines.
Grade Criteria
A Need supportive level 1 or 1+ evidence plus consensus*
B Need supportive level 2 or 2+ evidence plus consensus*
C Need supportive level 3 evidence plus consensus
D Any lower level of evidence supported by consensus
*An appropriate level of evidence was necessary, 
but not sufficient to assign a grade in recommen-
dation; consensus was required in addition. 
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SD below the mean for a young normal 
adult of the same sex).
2) Osteopenia (low BMD) is defined as a 
T-score between –1.0 and –2.5 SD. 
3) Osteoporosis is defined as a T-score be-
low –2.5 SD.
4) Severe osteoporosis is defined as a T-
score below –2.5 SD in the presence of 
one or more fragility fractures.
It should be noticed that this is just a den-
sitometric diagnosis that can be translated 
into a clinical diagnosis only after an over-
all clinical evaluation and differential diag-
nosis.
Furthermore, diagnostic T-score threshold 
does not equate the intervention thresh-
old, as other factors - both skeletal and 
non-skeletal - affect an individual’s frac-
ture risk and the decision of initiating drug 
treatment. 
ePIdeMIoLoGY
Osteoporosis places a relevant burden on 
society. The incidence of osteoporosis in-
creases with ageing, affecting most of the 
population after the eighth decade of life. 
It has been estimated that approximately 
3.5 million women and 1 million men have 
osteoporosis in Italy. As the proportion of 
individuals over the age of 65 years will in-
crease by 25% in the next 20 years in Italy, 
a proportional increase in osteoporosis in-
cidence is expected (1). 
The lifetime risk of osteoporotic fracture of 
the distal wrist, vertebral bodies or proxi-
mal femur is approximately 15% for each 
individual site and 40% for all sites.
The number of hip fractures in the Italian 
population aged 50 years or older is greater 
than 90,000 per year. Vertebral deformities 
have been found in over 20% of subjects 
aged 65 or older of both genders.
Osteoporotic fractures have important so-
cial and economic implications, besides the 
health burden. The 1-year mortality rate for 
patients with a fracture of the proximal fe-
mur is 15 to 30%. Osteoporotic fractures 
are one of the leading causes of death 
among the elderly, with an incidence com-
parable to that from stroke and breast can-
cer, and 4-fold that from endometrial can-
cer. Furthermore, in 50% of women with a 
hip fracture there is a substantial reduction 
in the level of independence, which leads 
to the need for long-term care in 20% of 
cases. 
n	 RISK FACTORS
The clinical relevance of osteoporosis is 
related to a reduction in bone strength that 
leads to an increase in the risk of fragility 
fractures from low-energy traumas. Bone 
resistance to trauma depends on both quan-
titative factors, such as BMD assessed by 
DXA, and qualitative factors, such as ge-
ometry, microstructure, inorganic and or-
ganic composition of the matrix, that are 
not routinely assessed in clinical practice. 
Low-energy fractures generally result from 
accidental falls from standing or simple 
activities of daily life. With falls, fracture 
probability depends on the characteristics 
of the fall, the effectiveness of protective 
responses, and the soft tissue attenuation 
of the impact energy. Clearly, factors that 
affect the risk of fall tend to increase the 
risk of fracture. Thus, multiple factors 
that affect both bone strength and the fre-
quency and type of traumas are involved in 
the pathogenesis of fractures. The risk of 
osteoporotic fracture results from a com-
bination of factors that act predominantly 
via a reduction in BMD and factors that are 
totally or partially independent from BMD 
(bone properties that cannot be assessed by 
BMD and extra skeletal factors). Clearly, 
this distinction is not clear-cut, and several 
risk factors act through different mecha-
nism simultaneously. Among factors that 
are independently associated with both 
osteoporosis and fracture risk, age, prior 
fragility fractures, family history of fragil-
ity fractures, corticosteroid use and condi-
tions that increase the likelihood of falls 
are of particular importance. Furthermore, 
the presence of comorbidities increases 
fracture risk. In subjects with several risk 
factors, fracture risk is higher than in sub-
jects with a single risk factor, including 
an isolated reduction in BMD. Therefore, 
BMD measurement is adequate for diag-
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nosing osteoporosis (diagnostic threshold), 
but combining BMD with independent risk 
factors is necessary to identify individuals 
at high risk of fracture requiring a specific 
pharmacological or non-pharmacological 
intervention, whatever appropriate, accord-
ing to the kind of risk factors mainly in-
volved. 
Main risk factors
• Bone mineral density
A reduction in BMD is an important risk 
factor for fractures. BMD is dependent 
on the peak bone mass achieved at matu-
rity and the subsequent bone loss associ-
ated with menopause and ageing, and is 
affected by genetic and nutritional factors, 
lifestyle, comorbid conditions and a num-
ber of drugs (Table V). Several prospective 
epidemiological studies have shown that 
for every 1 SD decrease in BMD [mostly 
assessed by DXA of axial sites (i.e., fem-
oral neck, total femur and lumbar spine)] 
there is a 1.5- to 3-fold increase in the risk 
of fracture. The ability of BMD to predict 
fractures is similar to that of blood pressure 
as a predictor of stroke, and better than that 
of cholesterol as a predictor of myocardial 
infarction. Nevertheless, despite BMD be-
ing an important risk factor for fracture, its 
predictive power increases when other in-
dependent risk factors that can provide ad-
ditional and complementary information to 
BMD are considered. 
• Age
With ageing, there is an exponential increase 
in the incidence of osteoporotic fractures. The 
risk of fracture associated with ageing is only 
in part mediated by a reduction in BMD, be-
ing largely dependent on other factors, such 
as qualitative alterations of bone structure, an 
increase in the rate of falls and slower protec-
tive responses. The same T-score has a dif-
ferent significance at different ages, and for 
a given BMD the risk of fracture is higher in 
the elderly than in the young.
• Previous fractures
A previous fragility fracture is a strong risk 
factor for future fractures in both genders. 
Even though a previous fracture is often as-
sociated with reduced BMD, the risk for new 
fractures is largely independent of BMD. 
Recent epidemiological studies showed 
that having a previous fracture of any site 
increases the risk of new fractures, al-
though to a different extent depending on 
the site. Vertebral fractures (including mor-
phometric fractures), as well as fractures 
of the wrist and humerus are of particular 
prognostic relevance (2-4). Furthermore, 
the risk is dependent on the number of pre-
vious fractures. The risk of new fractures 
in individuals with 3 or more fractures is 
approximately 10-fold higher compared to 
that in individuals with no fractures, and 2- 
to 3-fold higher compared to those with a 
single fracture (2, 5). 
• Family history
Fracture risk is affected by family history 
of fracture independently of BMD. Specifi-
cally, having a parent with a hip fracture 
significantly increases the risk of hip frac-
ture and, although to a lesser extent, of all 
osteoporotic fractures (6, 7).
• Comorbidities
Several disorders are associated with an 
increased fracture risk (Table V). The 
Table V - Risk factors for osteoporosis and/or os-
teoporotic fractures.
•	 Age
•	 Female	gender
•	 Low	body	mass	index
•	 Prior	fragility	fracture	(particularly	spine,	including	
morphometric fractures, wrist, hip and humerus)
•	 Family	history	of	hip/vertebral	fracture
•	 Cigarette	smoking	(current)
•	 Alcohol	intake	(3	or	more	units	per	day)
•	 Vitamin	D	deficiency
•	 Early	menopause	(before	the	age	of	45	years)	
•	 Low	physical	activity	
•	 Prolonged	immobility
•	 Reduced	calcium	intake
•	 Excessive	sodium	intake
•	 Osteoporosis-associated	diseased	
•	 Organ	transplant
•	 Drugs	
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risk is thought to be mediated by a reduc-
tion in BMD in many of these conditions. 
However, different mechanisms, such as 
chronic inflammation, altered bone qual-
ity, impaired health status, specific com-
plications, decreased mobility, decreased 
muscle mass/strength (sarcopenia) and in-
creased risk of falls may also play a role 
(Table VI). Vitamin D deficiency often co-
exists, representing a further negative fac-
tor. Comorbidities to be mentioned include 
rheumatoid arthritis and connective tis-
sue diseases, diabetes, chronic obstructive 
pulmonary disease, chronic inflammatory 
bowel diseases, AIDS, Parkinson’s disease, 
multiple sclerosis, conditions associated 
with severe motor disability. Of note, indi-
viduals with type 1 or type 2 diabetes tend 
to fracture at a higher BMD as compared to 
non-diabetic subjects, therefore the risk of 
fracture is partially independent of BMD in 
this population (7-15).
• Drugs
Several drugs have been associated with 
an increased fracture risk. The detrimental 
effects of corticosteroids on bone are well 
known. Although these are mainly medi-
ated by factors independent of bone den-
sity, corticosteroid treatment also leads to 
a rapid reduction in BMD. Among recent 
drugs, adjuvant hormone antagonist thera-
pies [aromatase inhibitors in women who 
have undergone surgery for breast cancer, 
gonadotropin releasing hormone (GnRH) 
agonists in men with prostate cancer] need 
special attention. Treatment with these 
drugs results in a progressive decrease in 
BMD, although a role for independent fac-
tors for fracture risk cannot be excluded.
Overall assessment of fracture risk
An integrated assessment of BMD in con-
junction with the main clinical risk factors 
that are totally or partially independent of 
BMD allows for a more accurate estimate 
of the risk for fragility fractures in the 
medium term (5 to 10 years), and to iden-
tify subjects requiring pharmacological or 
non-pharmacological treatment, whatever 
appropriate. In the past decade several al-
gorithms, e.g. FRAX® and DeFRA®, have 
been developed that estimate the 10-year 
risk of a major osteoporotic fracture (spine, 
hip, humerus or wrist fracture) by integrat-
ing information from BMD measurement 
and clinical risk factors. The identifica-
tion of clinical risk factors independent of 
BMD to be included in these algorithms 
was based on a number of studies and 
meta-analyses, as well as on their ease of 
identification and quantification. Risk as-
sessment, whether using or not these algo-
rithms, should be based on easily available 
information. When an algorithm includes 
too many variables, such as the QFracture, 
or variables that are not easily available, 
chances are that the algorithm or tool is not 
implementable in clinical practice due to 
its complexity, which would make it com-
pletely useless. On the other hand, how-
ever, when the definition of risk is based 
on few factors, maybe not even stratified 
- as in the Garvan fracture risk calculator 
- it is possible that the algorithm and risk 
stratification lack in accuracy, thereby not 
providing specific advantages over BMD 
measurement. 
Based on this background, and in order 
to overcome some of the limitations of 
FRAX® as well as to improve fracture risk 
prediction, the Italian DeFRA® - an algo-
rithm derived from FRAX® and based on 
data on fracture risk in the Italian popula-
Table VI - Risk factors for falls.
•	 Individual	factors
-  History of previous falls
-  Conditions that impair
Muscle mass/strength (sarcopenia)
Lower limb function
Balance
Vision
-  Cognitive impairment
-  Arrhythmias
-  Drugs (drugs that act on the CNS,  
anti-hypertensives, alcohol)
-  Muscle impairment due to hypovitaminosis D
•	 Environmental	factors
-  Barriers, lighting, flooring, shoes
CNS, Central nervous system.
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tion - was developed that more accurately 
stratifies some of the variables already in-
cluded in FRAX® (e.g. site and number of 
previous fractures, comorbidities). Given 
their great relevance, clinical risk fac-
tors independent of BMD have also been 
used in the definition of criteria for the 
reimbursement of drugs for the treatment 
of osteoporosis in Italy [Italian Medicines 
Agency (AIFA) Note 79]. The Note 79 was 
recently revised, which highlights the fact 
that tools for the assessment of fracture risk 
should be constantly and frequently updat-
ed with data from clinical studies that may 
identify new clinical risk factors (as in the 
case of diabetes and of aromatase inhibi-
tors), or may allow for a better interpreta-
tion of risk based on known factors.
GeNetICs oF osteoPoRosIs
Genes appear to be the main determinant of 
person-to-person variability in bone mass. 
Propensity to osteoporosis, similar to many 
other disorders, is attributable to the overall 
combined effect of several gene polymor-
phisms.
Polymorphisms of genes encoding type 
1 collagen (COLIA1), estrogen receptor 
(ER) and vitamin D receptor (VDR) are 
currently regarded as possible genetic de-
terminants of osteoporosis risk.
Each of these polymorphisms can explain 
less than 30% of variability in bone mass, 
and even less of the risk of developing os-
teoporosis. Diagnostic and prognostic use 
of gene polymorphisms is therefore not 
justified. 
n	 SECONDARY OSTEOPOROSIS 
Postmenopausal/senile osteoporosis should 
always be distinguished from secondary 
osteoporosis. A number of factors have the 
potential to induce osteoporosis, including 
several diseases and drugs (Table VII). Rec-
ommendations for the management of the 
most typical or frequent forms of secondary 
osteoporosis are provided below, focusing 
on the specific diagnostic and therapeutic 
aspects related to osteoporosis.
PRYMARY 
hYPeRPARAthYRoIdIsM
Definition. Epidemiology
Primary hyperparathyroidism (PHPT) is a 
disorder of calcium and phosphorus metab-
olism caused by an autonomous and rela-
tively uncontrolled secretion of parathyroid 
hormone (PTH) by one or more hyperfunc-
tioning parathyroid glands, resulting in 
hypercalcaemia. PHPT, together with hy-
percalcaemia of malignancy, accounts for 
90% of all hypercalcaemic states. PHPT 
is a very common endocrine disease, with 
an incidence of approximately 25/100,000 
persons-year in the male US population 
and 65/100,000 persons-year in the female 
US population; age-corrected prevalence 
is 85/100,000 in men and 233/100,000 in 
women (16). PHPT is more common in 
women (the female/male ratio is approxi-
mately 2:1, and increases up to 5:1 after the 
age of 75 years) (17). In most cases PHPT 
is caused by a single parathyroid adenoma 
(75-85%), whereas 15-20% of cases are 
caused by hyperplasia affecting more than 
one parathyroid gland. The finding of mul-
tiple adenomas is less frequent, and ma-
lignancies are rare (less than 1% of cases) 
(17). Approximately 10% of cases are fa-
milial, occurring as part of a multiple en-
docrine neoplasia (MEN1, MEN2A, other 
rare forms). Sometimes an adenoma may 
arise from an ectopic parathyroid gland 
(mainly in the mediastinum).
Diagnosis and differential diagnoses
PHPT should be suspected in all cases of 
hypercalcaemia, being the most common 
cause of such metabolic alteration in out-
patients. The diagnosis is primarily bio-
chemical, and is based on the finding of hy-
percalcaemia and PTH levels that are high 
or inappropriately normal relative to serum 
calcium levels. Near-normal calcium levels 
may be found in mild PHPT (normocal-
caemic primary hyperparathyroidism). In 
such cases, calcium levels should be mea-
sured several times and albumin-corrected 
calcium levels should be calculated (18). 
Furthermore, pharmacological causes (e.g., 
thiazide diuretics, lithium salts bisphos-
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Endocrine disorders
Hypogonadism
Hypercortisolism
Hyperparathyroidism
Hyperthyroidism
Hyperprolactinaemia
Diabetes mellitus type 1 and 2
Acromegaly
GH deficiency
Haematologic disorders
Myelo- and lymphoproliferative diseases
Multiple myeloma
Systemic mastocytosis
Thalassemia
Monoclonal gammopathies
Sickle cell anaemia
Haemophilia
Gastrointestinal disorders
Chronic liver disease 
Primary	biliary	cirrhosis	
Celiac disease 
Chronic inflammatory bowel disease 
Gastrointestinal resection 
Gastric bypass 
Lactose intolerance 
Intestinal malabsorption 
Pancreatic	insufficiency
rheumatic disorders
Rheumatoid arthritis
Systemic lupus erythematosus 
Ankylosing spondylitis
Psoriatic	arthritis
Scleroderma
Other	connective	tissue	diseases
Kidney diseases
Idiopathic renal hypercalciuria
Renal tubular acidosis
Chronic kidney disease
Neurologic disorders
Parkinson’s	disease
Multiple sclerosis
Paraplegia
Sequelae of stroke
Muscular dystrophies
Genetic disorders
Osteogenesis	Imperfecta
Ehlers-Danlos
Gaucher’s	disease
Glycogenosis
Hypophosphatasia
Haemochromatosis
Homocystinuria
Cystic fibrosis
Marfan syndrome
Menkes syndrome
Porphyria
Riley-Day syndrome
Other disorders
Chronic obstructive pulmonary disease
Anorexia nervosa
AIDS/HIV
Amyloidosis
Sarcoidosis
Depression
Table VII - Diseases associated with osteoporosis. 
phonates) should be ruled out, and hypovi-
taminosis D, when present, should be cor-
rected. Measurement of ionized calcium is 
justified only when performed in optimal 
technical conditions. Assays that measure 
intact PTH should be preferred. The find-
ing of reduced 24-h urine calcium man-
dates exclusion of familial hypocalciuric 
hypercalcemia (FHH), i.e., the other hyper-
calcaemic state (along with use of lithium 
salts or thiazide diuretics) where elevated 
PTH levels are seen.
As parathyroidectomy is not required and 
does not correct hypercalcaemia in FHH 
patients, it is important to make the cor-
rect differential diagnosis. A ratio between 
fractional excretion of calcium and creati-
nine clearance of <0.01 is typical of FHH 
patients, and is useful to differentiate them 
from patients with PHPT (19).
Preoperative localization of the adenoma 
or hyperplastic parathyroid [by ultrasonog-
raphy, sestamibi scintigraphy, or multidi-
mensional computed tomography (CT)] is 
not indicated during the diagnostic process. 
The usefulness of preoperative localization 
once the indication for surgery has been es-
tablished (although preoperative localiza-
tion is often used to facilitate surgical ex-
ploration) is debated, whereas localization 
is necessary prior to reoperation in patients 
with persistent PHPT (18). 
Clinical manifestations
In most instances, PHPT is diagnosed in 
the absence of symptoms. Severe mani-
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festations typical of PHPT (osteitis fibrosa 
cystica, nephrolithiasis- nephrocalcinosis, 
bone brown tumours) have become very 
rare since measurement of serum calcium 
has become routine clinical practice, as of 
the 1970s, allowing for an early diagnosis 
of disease. Kidney stones are present in 
approximately 10% of subjects at diagno-
sis, and are related to hypercalciuria; the 
incidence of US-detected stones is higher. 
Besides the risk of kidney stones, patients 
with overt PHPT are at increased risk of 
fracture, due to a reduction in bone mass 
(particularly in cortical bone, but also in 
trabecular bone). Surgical treatment of 
PHPT can reduce the recurrence of kid-
ney stones, as well as the risk of fracture 
(20, 21). Given its high frequency, PHPT 
should always be considered as a possible 
cause of osteoporosis. As such, measure-
ment of serum calcium should always be 
included among the first tier investigations 
to be performed in a patient with reduced 
bone mass. An acute hypercalcaemic crisis 
(parathyroid crisis) is a very rare presenta-
tion of PHPT. It is facilitated by dehydra-
tion and characterized by symptoms of 
severe hypercalcaemia, and is potentially 
deadly. Although an exceptional onset, an 
hypercalcaemic crisis should be considered 
in any patient with severe hypercalcaemia 
of unclear etiology. 
Treatment
• Surgical treatment
In the absence of contraindications, sur-
gery is the definitive and causal treatment 
of symptomatic PHPT (nephrolithiasis, 
symptomatic hypercalcaemia). The surgi-
cal procedure consists of neck exploration 
to identify all 4 parathyroid glands, and 
removal of the one(s) with adenomatous 
or hyperplastic features. The surgeon’s 
experience and intraoperative PTH mea-
surement are important in reducing the risk 
of persistent PHPT. Minimally invasive 
surgery of parathyroid glands (unilateral 
surgery based on scintigraphy) in conjunc-
tion with intraoperative PTH measurement 
is safe and can be as effective as bilateral 
neck exploration under general anaesthesia 
(Level of evidence 2). The role of surgery 
in the management of asymptomatic PHPT 
in patients aged >50 years is not clearly es-
tablished. With regard to the indications for 
parathyroidectomy, the present guidelines 
are in agreement with recommendations 
from the Fourth International Workshop on 
this topic, issued in 2014 (18):
- Serum calcium concentration ≥1.0 mg/
dL (0.25 mmol/L) above the upper limit 
of normal.
- Estimated glomerular filtration rate <60 
mL/min
- BMD T-score <-2.5 at the distal radius 
or spine and/or previous asymptomatic 
vertebral fractures (assessed by x-ray, 
CT, MRI or DXA morphometry)
- 24-hour urinary calcium >400 mg per 
day (>10 mmol/day)
- Nephrolithiasis or nephrocalcinosis di-
agnosed by x-ray, ultrasound or CT
- Age <50 years 
Surgery is also indicated for patients who 
cannot be followed up or in case of patient 
preference for surgery, even if the above in-
dications are not met, and in the absence of 
contraindications.
In patients who do not meet the criteria for 
parathyroidectomy, supportive and preven-
tive measures in conjunction with adequate 
monitoring should be implemented (18):
- Measurement of serum calcium, creati-
nine and estimated glomerular filtration 
rate yearly.
- DXA (of all 3 sites) every 1 to 2 years.
- 24-hour urinary calcium, abdominal 
x-ray or ultrasound only when kidney 
stones are suspected.
If during follow up a change in the clini-
cal picture leads to satisfaction of the above 
criteria, the patient should be addressed to 
surgery. 
General recommendations for patients not 
undergoing surgery include: i) avoid fac-
tors that may aggravate hypercalcaemia 
[thiazide diuretics, lithium salts, volume 
depletion, bed confinement or inactiv-
ity, and excessive calcium dietary intake 
(>1000 mg per day)]; ii) maintain an ad-
equate intake of calcium (800-1000 mg per 
day) and vitamin D (400-800 IU/day, in 
order to maintain serum hydroxy-vitamin 
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D levels of at least 20-30 ng/mL), avoid-
ing hydroxylated derivatives; iii) physical 
activity should be encouraged; iv) adequate 
hydration (at least 6-8 glasses of water per 
day) should be encouraged to reduce the 
risk of nephrolithiasis. 
• Medical therapy
Medical therapy for the control of severe 
hypercalcaemia is indicated in patients with 
contraindications to surgery or in prepara-
tion for surgery, and consists of adequate 
hydration with saline (2-4 L/day for 1-3 
days on average), use of loop diuretics (fu-
rosemide) once volume has been restored, 
and use of i.v. bisphosphonates (e.g., a sin-
gle dose of zoledronic acid 4 mg or pami-
dronate 60-90 mg). If quick correction of 
calcium levels is required (e.g. in the case 
of parathyroid crisis), administration of 4 
U/Kg of i.m. or s.c. calcitonin can be con-
sidered. If surgery for parathyroidectomy 
is scheduled within few days, i.v. bisphos-
phonates should be avoided (for possible 
worsening of postoperative hypocalcae-
mia). Although direct evidence is lacking 
(level 3), it is reasonable to recommend use 
of oral bisphosphonates (alendronate) if 
osteoporosis is present. Hormone replace-
ment therapy or raloxifene may be indicat-
ed in postmenopausal women who have no 
contraindications. Further studies are nec-
essary to establish the long-term benefit of 
cinacalcet, a calcimimetic that selectively 
inhibits PTH secretion. This drug is ap-
proved both for the treatment of secondary 
hyperparathyroidism in patients with end-
stage renal disease on maintenance dialysis 
therapy and for the reduction of hypercal-
caemia in patients with parathyroid car-
cinoma or patients with PHPT for whom 
parathyroidectomy would be indicated, but 
in whom parathyroidectomy is not clini-
cally appropriate or is contraindicated.
GLUCoCoRtICoId-INdUCed
osteoPoRosIs
Epidemiology and clinical manifestations
Chronic exposure to glucocorticoids, either 
due to increased endogenous production 
(Cushing’s syndrome) or exogenous intake 
(treatment of inflammatory or autoimmune 
diseases) is an important cause of osteopo-
rosis and fractures. In fact, glucocorticoids 
stimulate bone resorption by osteoclasts, 
reduce bone formation by inhibiting os-
teoblast proliferation and differentiation as 
well as by favouring osteoblast and osteo-
cyte apoptosis, alter calcium metabolism by 
reducing intestinal calcium absorption and 
by increasing renal excretion, and reduce 
androgen and estrogen secretion mainly by 
inhibiting pituitary gonadotropin secretion 
(22). Glucocorticoid-induced bone loss is 
an early event (in the first weeks of treat-
ment), and is more pronounced during the 
first 6 to 12 months of treatment, mainly 
affecting trabecular bone (particularly, ver-
tebral fractures occur early after initiation 
of steroid therapy). Thereafter, there is a 
reduction in osteoclast-mediated bone re-
sorption but inhibition of bone formation 
is maintained: bone loss is slower but con-
stant, also involving cortical bone (22, 23). 
Fragility fractures occur in 30 to 50% of 
patients in the first 5 years of long-term 
glucocorticoid therapy. Fracture probabil-
ity is further increased in the presence of 
other risk factors, particularly advanced 
age, previous fractures and menopause in 
women. Fractures may occur at any skel-
etal site, with predominance at sites with 
predominantly trabecular bone: spine, rib, 
and proximal femur (22). The incidence of 
fractures is related to the dose and duration 
of glucocorticoid therapy, and is also af-
fected by the underlying disease for which 
glucocorticoid therapy is indicated (e.g., 
rheumatoid arthritis, inflammatory bowel 
disease). Although low doses are less det-
rimental than higher doses, there is contro-
versy as to whether there is a threshold be-
low which no bone damage occurs. There 
is also much controversy about the negative 
impact of inhaled glucocorticoids on bone 
health. Inhaled glucocorticoids are certain-
ly less detrimental to bone as compared to 
systemic glucocorticoids, although doses 
>800 mcg/day of budesonide (or equiva-
lents) may be associated with accelerated 
bone loss and increased risk of fractures, 
especially with long-term use (24-26). It 
is important to remember that fracture risk 
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in glucocorticoid-induced osteoporosis is 
much higher as compared to that expected 
based on DXA BMD values, and rapidly 
decreases after treatment discontinuation 
(27, 28). Both of these observations have a 
practical implication: prevention should be 
started as early as possible, independent of 
BMD values, and prior to the occurrence 
of irreversible alterations of bone microar-
chitecture. 
Treatment
• Identification of patients to be tested 
and treated
Most guidelines set the threshold for in-
tervention at a dose of 7.5 mg per day of 
prednisone (or equivalent doses of other 
glucocorticoids). However, it is known that 
doses between 2.5 and 7.5 mg per day of 
prednisone are associated with an increased 
risk of fracture. Besides the daily dose, du-
ration of glucocorticoid therapy appears to 
be very important. Fracture risk increases 
significantly after only 3 months of treat-
ment, and decreases rapidly after discon-
tinuation of treatment. Glucocorticoid-in-
duced bone damage is largely independent 
of bone mass, and the lumbar spine T-score 
threshold to identify patients who need pre-
vention and treatment is set between –1.5 
and –1.0 (which equals to state that risk is 
essentially independent of bone mass, and 
is significant even for a T-score in the nor-
mal range). 
The present guidelines recommend phar-
macological treatment for the prevention 
of glucocorticoid-induced osteoporosis in 
postmenopausal women or men aged ≥50 
years who are receiving or planning to re-
ceive glucocorticoid therapy with ≥5 mg 
prednisone or equivalent for ≥3 months. 
• Interventions with proven efficacy
1. General measures: glucocorticoid ther-
apy should be reduced to the lowest pos-
sible dose and duration compatible with the 
need of controlling the underlying disease. 
Whenever possible, topical formulations 
(e.g., inhaled steroids or enemas for asth-
ma and inflammatory bowel diseases, re-
spectively) should be preferred over oral or 
parenteral administration. Patients should 
be encouraged to take adequate weight-
bearing exercise to counteract the loss of 
bone and muscle mass. Cigarette smoking 
and excessive alcohol consumption should 
be avoided, and measures to reduce the risk 
of falls should be considered (29) (Grade A 
recommendation).
2. Calcium and vitamin D: supplementa-
tion with 1000-2000 mg per day of cal-
cium and 500-800 International Units (IU) 
per day of vitamin D was shown effective 
in decreasing glucocorticoid-induced bone 
loss (30) (Level 1b). Supplementation 
with hydroxylated metabolites of vitamin 
D does not appear to offer additional ad-
vantages over cholecalciferol. As in the 
studies that showed the anti-fracture effi-
cacy of bisphosphonates patients were also 
supplemented with calcium and vitamin D, 
these should be recommended for all pa-
tients treated or planned for treatment with 
bisphosphonates (Grade A recommenda-
tion).
3. Hormone replacement therapy: gluco-
corticoids reduce the production of sex 
hormones. As such, it appears rationale 
to replace sex hormones in women with 
amenorrhea and estrogen deficiency (hy-
pothalamic amenorrhea or primary ovarian 
insufficiency) or in men with proven hypo-
gonadism (31, 32). While estrogen therapy 
is no longer considered a first line therapy 
for the prevention of postmenopausal os-
teoporosis, it appears reasonable – in the 
absence of contraindications – to consider 
hormone replacement therapy in premeno-
pausal women with estrogen deficiency or 
in men with hypogonadism treated with 
glucocorticoids, even if controlled studies 
on the incidence of fractures are lacking 
(Grade A recommendation).
4. Bisphosphonates: bisphosphonates, 
particularly alendronate, risedronate and 
zoledronate, are the most widely used 
drugs for the prevention and treatment of 
glucocorticoid-induced osteoporosis in 
postmenopausal women and men. Ran-
domized, controlled trials are available on 
these bisphosphonates (Level of evidence 
1a), although underpowered to detect a re-
duction in fractures as a primary endpoint 
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(33-35). The efficacy of bisphosphonates 
in reducing fractures can be inferred from 
meta-analyses or post-hoc analyses (36, 37) 
(Level of evidence 2). Therefore, bisphos-
phonate therapy in postmenopausal women 
and in men should be recommended as first 
line for the primary prevention, and should 
be started at the beginning of glucocorti-
coid therapy (Grade A recommendation).
5. Teriparatide: in a 36-month study that 
compared teriparatide versus alendronate 
in patients treated with glucocorticoids, 
teriparatide was more effective than alen-
dronate in improving BMD (primary end-
point) and incidence of vertebral fractures 
(secondary endpoint) (38). For this reason, 
treatment with teriparatide is considered as 
a first line option for patients with gluco-
corticoid-induced osteoporosis and at least 
one previous fracture (secondary preven-
tion) in the recent revision of the Italian 
AIFA Note 79. Treatment with teripara-
tide, as per the summary of characteristics, 
should not exceed 24 months. After this 
time, if glucocorticoid therapy is continued 
and fracture risk persists, patients should 
be switched to antiresorptive therapy to 
maintain the anti-fracture effect and the 
gain in terms of BMD. 
6. Denosumab: in a post-hoc analysis of 
a randomized controlled study in patients 
with rheumatoid arthritis (some of them 
treated with glucocorticoids), denosumab 
was shown to induce a significant increase 
in lumbar spine and hip BMD versus pla-
cebo (39). In the AIFA Note 79 denosumab 
is considered as a second-line therapy both 
for primary and secondary prevention in 
patients treated with glucocorticoids. 
osteoPoRosIs ReLAted  
to otheR dRUGs
Several drug classes have been associated 
with osteoporosis and fragility fractures. 
Many of these data come from epidemio-
logical and retrospective studies, and the 
level of evidence is often very low. Further-
more, a clear pathophysiological rationale 
is lacking for many of these associations, 
and is not known for some (Table VIII) 
(40-42). Besides glucocorticoid therapy 
and aromatase and GnRH inhibitors, which 
are treated separately in these guidelines, 
Table VIII - Drugs associated with bone loss.
Drug class active substance Possible mechanism of action
Glucocorticoids* Hydrocortisone, prednisone, dexamethasone Inhibition of osteoblast activity/osteocyte apoptosis
Aromatase inhibitors* Letrozole, anastrozole, examestane Hypogonadism with high turnover
SSRIss* Citalopram, fluoxetine, paroxetine Inhibition of osteoblast proliferation, RANKL activation
Proton	pump	inhibitors* Esomeprazole,	omeprazole,	lansoprazole Reduced calcium intestinal absorption
H2-inhibitors Ranitidine, cimetidine Reduced calcium absorption
Thiazolidinediones* Rosiglitazone, pioglitazone Inhibition of bone formation and osteoblast 
differentiation 
Thyroid hormone (excess)* Levothyroxine Increased bone turnover 
Anticoagulants* Heparin, warfarin Reduced osteocalcin activity
Anticonvulsants* Phenobarbital,	valproic	acid,	oxcarbazepine,	phenytoin Altered vitamin D metabolism
GnRH* Leuprolide, goserelin Hypogonadism with high turnover
Loop diuretics Furosemide Calciuric effect
Antiretroviral agents Efavirenz,	nevirapine
Tenofovir
Protease	inhibitors
Altered vitamin D metabolism
Increased urinary phosphate excretion 
Inhibition of osteoblastogenesis/increased RANKL
Calcineurin inhibitors* Ciclosporin A (high doses), tacrolimus Increased bone turnover. Increased RANKL expression
Parenteral	nutrition Unclear
*Evidence	for	an	association	with	fracture	risk.	SSRI,	selective	serotonin	reuptake	inhibitors;	GnRH,	gonadotropin-releasing	hormones.
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there is a strong association between some 
drugs categories and fragility fractures. A 
significant increase in the risk of vertebral 
fractures [6 studies: odds ratio (OR) 1.50; 
95% confidence interval (CI) 1.32-1.72] 
and hip fractures (10 studies: OR 1.23; 95% 
CI 1.11-1.72) with proton pump inhibitors 
(PPIs) has been demonstrated, especially 
when treatment exceeds 12 months (43). 
An association between use of selective 
serotonin reuptake inhibitors (SSRIs) and 
hip fractures is present in the first year of 
treatment, for both genders, especially af-
ter the age of 70 years (44). Levothyrox-
ine (if in excess) is associated with an in-
creased risk of fractures in both men and 
women (OR 1.98; 95% CI 1.15-1.76) (45). 
The use of pioglitazone and rosiglitazone 
is associated with a significant increase (3- 
to 4-fold) in the risk of hip and humerus 
fractures in postmenopausal women (46). 
A large body of evidence is available on 
the association of some first generation an-
ticonvulsants (carbamazepine, oxcarbaze-
pine, phenobarbital, phenytoin, primidone) 
with low bone mass, as well as with a 2- to 
6- fold increased risk of hip fracture in pa-
tients with epilepsy, especially when poly-
medicated (47). The use of cyclosporine 
in transplanted patients is associated with 
an increase in clinical fractures that ranges 
from 10% to 34% in the first year of treat-
ment (48). Long-term use of unfractioned 
heparin increases fracture risk by 2.5% 
to 5%, whereas there are no data on low 
molecular weight heparin. There is contro-
versy in the literature about the effect of 
warfarin on risk of osteoporosis and frac-
tures (42, 49). Some drug categories may 
interfere with the anti-fracture efficacy of 
bisphosphonates. A possible dose-depen-
dent attenuation of the anti-fracture effect 
of alendronate and risedronate by PPIs has 
been reported in 4 epidemiological studies 
(two retrospective and two cohort studies), 
although this effect was not confirmed in 
a post-hoc analysis of three RCTs on rise-
dronate (40). In a retrospective study in 
which alendronate was co-administered 
with SSRIs, there was a significant asso-
ciation with the risk of major osteoporotic 
fractures. There are no studies on the ef-
fect of bisphosphonates co-administered 
with drugs potentially detrimental to bone 
health (40). 
Adjuvant hormonal therapy 
The substantial hypoestrogenism induced 
by adjuvant hormonal therapy with aroma-
tase inhibitors or tamoxifene + LHRH ana-
logues in women with breast cancer, and 
the androgen deprivation induced by GnRH 
agonists and/or antiandrogens in men with 
prostate cancer, lead to an accelerated bone 
loss and rapidly increase fracture risk (50-
53). There is a substantial difference in 
the rate of bone turnover, and thereby in 
the rate of bone loss, among different pa-
tient populations (men, premenopausal 
and postmenopausal women at diagnosis) 
and with different types of antihormonal 
therapy (chemotherapy-induced meno-
pause, GnRH with or without tamoxifen, 
or aromatase inhibitors from oils, andro-
gen deprivation therapy). Patient categories 
at the highest risk of osteoporosis are (in 
descending order): premenopausal women 
with chemotherapy-induced menopause 
treated with GnRH agonists, men on an-
drogen deprivation, women switched from 
tamoxifen to aromatase inhibitors, women 
on aromatase inhibitors, especially if aged 
<70 years (52, 54, 55).
Given the high prevalence of risk factors 
for fractures, irrespective of hormone ther-
apy, and the high prevalence of vertebral 
fracture at cancer diagnosis, all subjects 
with breast or prostate cancer should be 
assessed for fragility fractures (including 
morphometric vertebral fractures) (56, 57).
Aminobisphosphonates and denosumab 
are the first line drugs for the management 
of bone health in breast and prostate can-
cer, being able to prevent BMD loss during 
adjuvant hormonal therapy. The bisphos-
phonates alendronate, risedronate and 
ibandronate have been used in both men 
and women, at the same doses used for 
fracture risk reduction in postmenopausal 
osteoporosis (58, 59). Zoledronic acid has 
been used at doses double those used in 
postmenopausal osteoporosis (4 mg every 
6 months) on average, with effects similar 
to those achieved in postmenopausal os-
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teoporosis (60). Data on the anti-fracture 
efficacy of bisphosphonates in this patient 
population are lacking. Anti-fracture effi-
cacy has been demonstrated for denosum-
ab 60 mg every 6 months, both in prostate 
cancer patients for spine fractures and in 
postmenopausal women treated with aro-
matase inhibitors for all clinical fractures 
(vertebral and non-vertebral) (61, 62). 
Denosumab, at a dose of 60 mg every 6 
months, may reduce all vertebral and non-
vertebral fractures by 50%, and new ver-
tebral fractures by 60%. The anti-fracture 
effect is independent of age, duration of 
hormonal therapy and BMD value. In other 
patient populations (premenopausal wom-
en treated with GnRH agonists, women 
with chemotherapy-induced menopause) 
only the treatment effect on BMD has been 
evaluated. However, at the same doses used 
in postmenopausal or male osteoporosis, 
the magnitude of effect on BMD in cancer 
treatment-induced bone loss (CTIBL) was 
comparable, which suggests a similar anti-
fracture effect (58).
There is no international consensus on the 
intervention threshold for the prevention 
of CTIBL and CTIBL-related fractures. 
Over time, an increasingly conservative 
threshold has been considered, up to near-
normal, especially in the presence of other 
independent risk factors (58, 59).
However, based on the following factors: 
i) the lack of evidence for a validated T-
score threshold (only based on expert opin-
ion) and the uncertainty on the predictive 
value of BMD for fracture risk in this pa-
tient population; ii) a particularly fast rate 
of bone loss in all forms of osteoporosis 
induced by adjuvant hormonal therapy, 
as an independent risk factor; iii) a very 
high prevalence of osteoporosis/fractures 
and/or other risk factors for fracture in pa-
tients with breast or prostate cancer; iv) the 
strong evidence that treatment with antire-
sorptives is more effective when used be-
fore than after a fracture or BMD loss has 
occurred, in both men and women (either 
pre- or post-menopausal) (60, 63); v) the 
evidence that fracture risk reduction (with 
denosumab) is independent of BMD values 
at initiation of antiresorptive therapy (61).
These guidelines recommend the use of 
bisphosphonates or denosumab at initiation 
of adjuvant hormonal therapy or at the on-
set of chemotherapy-induced amenorrhea 
(www.aiom.it 2015 guidelines).
The optimal duration of bisphosphonates 
or denosumab therapy for osteoporosis in 
women with breast cancer or men with 
prostate cancer has not been established. 
For women with breast cancer and for men, 
it is reasonable to recommend continuing 
treatment through the duration of treatment 
with GnRH and/or aromatase inhibitors 
and androgen deprivation. Data supporting 
this recommendation are indirect (58, 64). 
osteoPoRosIs IN ChRoNIC 
KIdNeY dIseAse ANd oRGAN 
tRANsPLANtAtIoN
Fragility fractures are among the most 
frequent complications of chronic kidney 
disease (CKD) and in organ-transplanted 
patients. In recent years, a large number of 
epidemiological studies have shown that 
the incidence of hip fractures among indi-
viduals on dialysis is at least 3-fold that in 
the general population (Level of evidence 
1) (65, 66). Furthermore, it is known that 
mortality from hip fractures in these sub-
jects is at least twice that in the general 
population, as early as in the first year after 
the fracture event.
Furthermore, the prevalence of vertebral 
fractures is approximately 50% among 
subjects on periodic dialysis (Level of 
evidence 3). These data are not surprising 
when considering the many factors that 
contribute, in most subjects with end-stage 
renal disease, to the development of renal 
osteodystrophy, i.e., a condition character-
ised by a range of bone disorders (Table 
IX) and known for inducing extreme bone 
fragility. 
Epidemiological data on organ transplant 
are less accurate, due to the relatively small 
number of patients included in available 
studies (67, 68). However, it is known that 
the estimated prevalence of fragility frac-
tures is approximately 10-15% among 
subjects waiting for solid organ transplan-
tation (kidney, heart, liver, lung), due to 
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the negative effects of the underlying dis-
ease on bone. The proportion of patients 
with osteoporosis increases dramatically 
after transplantation. Bone loss is maxi-
mal in the first year after transplantation 
and may persist afterwards, although at a 
slower rate (67-69). After transplantation, 
more than 10% and approximately 50% 
of subjects with renal disease experience 
fragility fractures in the appendicular skel-
eton and vertebral fractures, respectively. 
Among liver, heart or lung transplanted 
patients, the incidence of vertebral fragility 
fractures is maximal in the first three years 
after organ transplantation, being approxi-
mately 30-40% and increasing to approxi-
mately 50% in the following years (Level 
of evidence 3). The main risk facture for 
fractures is immunosuppressive therapy, 
particularly glucocorticoid therapy, which 
is initially administered at high doses and 
continued for indefinite time in most pa-
tients. Other important risk factors, in all 
types of transplant patients, include age, 
female gender (in the long term). Factors 
specifically related to the organ disease 
may be crucial for the development of bone 
fragility. The most representative example 
is persistent secondary hyperparathyroid-
ism, sometimes severe and very long term, 
which involves up to 50% of kidney trans-
planted patients, even in the presence of a 
well-functioning graft.
Recommendations
The use of DXA for fracture risk prediction 
in patients with CKD or on dialysis is not 
well standardized. Densitometric values by 
DXA can be interpreted similar to those 
from patients with normal kidney function 
only in patients with CKD stage 1-3 [glo-
merular filtration rate (GFR) ≥30 mL/min] 
(Level of evidence 2). The reason for this 
lies in the fact that the bone disorder found 
in these subjects is very similar to osteopo-
rosis of subjects with normal kidney func-
tion. Therefore, these subjects should al-
ways undergo DXA assessment to evaluate 
bone fragility (Grade A recommendation). 
In subjects wit CKD stage 4-5 and 5D (i.e. 
with residual kidney function ≤29 ml/min 
or on dialysis), measurement of BMD does 
not appear to adequately predict the risk of 
fracture, and cannot differentiate among 
the different components of renal osteo-
dystrophy (Table IX, Level of evidence 1).
DXA should always be performed in 
organ-transplanted patients (69), imme-
diately after transplantation and every 18 
months thereafter for the first three years 
(Grade B recommendation). A spine x-ray 
should be taken every year, at least for the 
first 2 to 3 years following transplantation, 
to assess vertebral fractures (Grade C rec-
ommendation). 
Prevention of fragility fractures, espe-
cially of vertebral fractures, is effectively 
achieved in subjects with CKD stage 1-3, 
with the same efficacy and safety as in pa-
tients with normal kidney function, using 
alendronate, risedronate, denosumab and 
teriparatide (Level of evidence 1b, Grade A 
recommendation). Data on the efficacy of 
denosumab in a very small number of sub-
jects with CKD stage 4 are available, but 
do not allow drawing definite conclusions. 
Bisphosphonates and teriparatide have not 
been adequately assessed in patients with 
CK stage 4-5 and 5D, and are generally 
contraindicated in these patients.
There is insufficient evidence available 
from randomized, controlled, double blind 
studies on the anti-fracture efficacy in post-
transplant osteoporosis with any drug.
Alendronate, pamidronate, ibandronate 
and zoledronate have been shown to in-
Table IX - Renal osteodystrophy: histological classification.
renal osteodystrophy subtypes Bone turnover Bone mineralisation
Osteitis fibrosa High Normal
Osteomalacia Normal Low
Adynamic bone disease Low Normal
Mixed bone disease High Low
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crease bone mass, without causing relevant 
adverse events, and particularly without af-
fecting renal function (Level of evidence 
2). Several studies, although in a very small 
number of patients, have shown a prophy-
lactic effect of intravenous ibandronate, 
pamidronate and zoledronic acid on verte-
bral fractures, with no significant adverse 
events and no significant changes in kidney 
function in kidney transplanted patients 
(Level of evidence 4).
With regard to the vitamin D endocrine sys-
tem, it is known that progressive impairment 
of kidney function induces a substantial re-
duction in the active metabolite calcitriol, 
accounting for most metabolic alterations 
involved in the development of renal osteo-
dystrophy (Level of evidence 1). In subjects 
with CKD stage 4-5 and 5D whose PTH 
levels are particularly high (5-fold above 
the upper limit of normal) and progressively 
increasing, calcitriol and its analogues, as 
well as vitamin D analogues (paracalcitol in 
particular) can decrease PTH levels and im-
prove alterations of bone metabolism (Level 
of evidence 1a, Grade A recommendation), 
except for patients with adynamic bone dis-
ease. However, in recent years it has been 
recognized that 25-OH-vitamin D deficiency 
is present in nearly 90% of subjects, with or 
without advanced CKD (Level of evidence 
2). Measurement of serum 25(OH)vitamin D 
is highly recommended for all subjects with 
CKD (Grade B recommendation).
Supplementation with cholecalciferol and 
native vitamin D can substantially and sig-
nificantly reduce PTH levels in subjects 
with CKD 1-5 and 5D (Level of evidence 4).
Similarly, hypovitaminosis D is present in 
a significant proportion of organ-transplant-
ed patients (70), up to over 80% (Level of 
evidence 3). Supplementation with chole-
calciferol and calcidiol is strongly recom-
mended (Grade B recommendation), with 
dosing regimens similar to those used in the 
general population (Level of evidence 3).
n	 DIAGNOSIS 
dIAGNostIC PRoCedURes
Bone densitometry
Bone mass assessed as BMD can be mea-
sured by different techniques that are gener-
ally identified as bone densitometry. Bone 
densitometry allows measuring bone mass 
rather accurately and, at present, is the best 
predictor of osteoporotic fracture risk.
A densitometric diagnosis of osteoporosis 
(71-73) is based upon the comparison be-
tween the BMD value of the subject being 
examined, expressed as SD, and the mean 
BMD in the young normal subjects [peak 
bone mass; (T-score)]. BMD may also be ex-
pressed in relation to the mean BMD for sub-
jects of the same age and gender (Z-score).
It should be noticed that, according to the 
WHO, the threshold for diagnosing osteo-
porosis (T-score <-1.5 SD) is only applica-
ble to BMD values obtained by DXA.
The WHO criteria for the diagnosis of os-
teoporosis are not applicable to premeno-
pausal women nor to men younger than 50 
years (Table X).
Techniques for assessing bone  
mineral density
At present, DXA is the preferred technique 
for assessing bone mass, allowing for diag-
nosing osteoporosis, fracture risk prediction 
and follow-up. It is a DXA technique that al-
lows the assessment, virtually for each skel-
Table X - Use of T-score and Z-score in densitometry reporting.
T-score Z-score
In postmenopausal women and men older 
than	50	years	use	the	WHO	BMD	diagnostic	
classification.
In premenopausal women and in men younger than 50 years.
If the Z-score is -2 SD or lower, BMD is defined  
as below the expected range for age.
if the Z-score is above than -2 SD BMD is defined  
as within the expected range for age.
WHO,	World	Health	Organization;	BMD,	bone	mineral	density.
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etal site, of bone mineral content (BMC, g/
cm of bone segment) projected onto a bone 
area, to obtain a parameter defined as BMD 
(g/cm2 of bone segment). BMD correlates 
with fracture risk: for every 1 SD decrease in 
BMD (approximately 10%), there is a 1.5-3 
fold increase in fracture risk at any site. In 
general, BMD measured at one site provides 
a more accurate estimate of fracture risk for 
that site (Table XI). 
As vertebral and hip fractures are the most 
clinically relevant osteoporotic fractures, 
lumbar spine and proximal femur are the 
most frequently assessed sites. 
The accuracy of the densitometric measure-
ment is diminished by possible interfering 
conditions, which should be taken into ac-
count when reporting or performing the 
measurement. As an example, a vertebral 
fracture or a vertebra with focal degenera-
tive arthritic changes should be excluded 
from the densitometric analysis. However, a 
minimum of two lumbar vertebrae should be 
available for DXA reporting. Lumbar densi-
tometric assessment is often less accurate in 
individuals aged over 65 years, due to the 
presence of arthrosic manifestations, extra-
skeletal calcifications or vertebral fractures. 
For these reasons, femoral densitometry 
may be preferred after this age. 
Recommendations on bone mineral 
density measurement sites by dual-energy 
x-ray absorptiometry
Central DXA measurement is recommend-
ed for lumbar spine (L1-L4) and proximal 
femur:
1) Lumbar spine: i) vertebrae with struc-
tural abnormalities such as fractures, focal 
lesions or other abnormalities should be 
excluded from the analysis; ii) vertebrae 
should also be excluded if there is a T-score 
difference of more than 1.0 compared to 
the adjacent vertebrae; iii) a minimum of 
2 lumbar vertebrae must be evaluable in 
order for the assessment to be considered 
sufficiently accurate.
2) Proximal femur: BMD of both femoral 
neck and total hip should be assessed for 
diagnostic purposes, and the lowest value 
should be considered.
The lowest T-score among the 3 sites 
(spine, total hip or femoral neck) should 
be considered for densitometric classifica-
tion. A diagnosis of osteoporosis shouldn’t 
be based only on a densitometric report; it 
also requires a clinical evaluation. 
Peripheral measurements, e.g., at the fore-
arm, should be limited to the following 
situations: i) patients in whom the lumbar 
and/or hip assessment is not feasible or not 
accurate; ii) severely obese patients; iii) 
hyperparathyroidism.
Recently, DXA software programs that al-
low to assess some geometric parameters 
related to bone strength have been de-
veloped, such as the hip structure analy-
sis (HAS) and the trabecular bone score 
(TBS). TBS is a software program that, 
once added to the DXA system, analyzes 
the level of inhomogeneity of the vertebral 
densitometric scan, providing indirect in-
formation on trabecular microarchitecture. 
Studies published so far show that TBS 
Table XI -	Fracture	risk	predictive	ability	of	dual-energy	x-ray	absorptiometry	and	ultrasound	techniques	for	different	sites.	Values	
represent the increase in relative risk (95% confidence intervals) for every 1 standard deviation decrease (T-score). 
BmD measurement site
relative risk of fracture
Forearm Hip Vertebral all
DXA	Proximal	radius 1.8 (1.5-2.1) 2.1 (1.6-2.7) 2.2 (1.7-2.6) 1.5 (1.3-1.6)
DXA Distal radius 1.7 (1.4-2.0) 1.8 (1.4-2.2) 1.7 (1.4-2.1) 1.4 (1.3-1.6)
DXA Femur 1.4 (1.4-1.6) 2.6 (2.0-3.5) 1.8 (1.1-2.7) 1.6 (1.4-1.8)
DXA Lumbar spine 1.5 (1.3-1.8) 1.8 (1.2-2.2) 2.3 (1.9-2.8) 1.5 (1.4-1.7)
DXA Calcaneus 1.6 (1.4-1.8) 2.0 (1.5-2.7) 2.4 (1.8-3.2) 1.5 (1.3-1.8)
Ultrasound Calcaneus - 2.2 (1.8-2.7) 1.8 (1.5-2.2) 1.5 (1.4-1.7)
Ultrasound phalanxes - 1.9 (1.5-2.4) 1.6 (1.4-1.9) 1.4 (1.3-1.6)
BMD, bone mineral density; DXA, dual-energy x-ray absorptiometry.
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is associated with an improvement in the 
ability of predicting fracture risk as com-
pared to BMD alone. This application was 
approved by the Food and Drug Adminis-
tration (FDA), although its clinical utility 
has yet to be established. 
Quantitative computerized tomography 
Quantitative computerized tomography 
(QCT) allows measurement of volumet-
ric BMD (g/cm3) of the spine and hip, 
both total and compartmental, being able 
to separate trabecular BMD form cortical 
BMD. There is sufficient evidence sup-
porting the predictive ability of QCT for 
vertebral, but not for hip, fracture risk in 
postmenopausal women. There is lack of 
sufficient evidence for fracture prediction 
in men. Furthermore, QCT is associated 
with a high amount of radiation exposure 
of patients (approximately 100 µSv). At 
present, DXA is preferred over spine QCT 
for its precision, shorter scanning time, 
more stable calibration, lower radiation 
exposure and lower cost. A QCT for mea-
suring peripheral bone sites (pQCT) is also 
available. Besides the measurement of total 
and compartmental volumetric BMD at the 
radius and tibia, pQCT allows measuring 
some geometric parameters related to bone 
strength (cortical thickness, cross-sectional 
area, moments of inertia, etc.). Radiation 
exposure for each measurement is low 
(approximately 5 µSv). There is sufficient 
evidence for its predictive ability only for 
hip fractures in postmenopausal women. At 
present, pQCT has not a specific role in the 
diagnostic workup of osteoporosis. High-
resolution pQCT (HR-pQCT) has high 
spatial resolution, therefore it can be used 
to assess some bone microarchitecture pa-
rameters (trabecular thickness, cortical po-
rosity, etc.) with good accuracy. However, 
there is insufficient evidence on its ability 
to improve prediction of fragility factures, 
and its use is currently confined to the re-
search setting. 
 
Quantitative ultrasound 
Quantitative ultrasound (QUS) provides 
two parameters (speed and attenuation) 
that serve as indirect indices of bone mass 
and structural integrity, and that are mainly 
measured at two sites, i.e., phalanxes and 
heel. It has been shown that ultrasound-de-
rived parameters are not inferior to lumbar 
or hip DXA in predicting the risk of osteo-
porotic fractures (hip and spine), both in 
postmenopausal women and in men (Table 
XI). Bone US does not measure bone den-
sity directly. Conflicting results from US 
and DXA are not surprising nor infrequent, 
and are not necessarily indicative of an er-
ror. Rather, QUS parameters are indepen-
dent predictors of fracture risk, as they are 
affected by other bone characteristics. As 
such, QUS cannot be used for diagnosing 
osteoporosis with the WHO criteria (T-
score <-2.5). The heterogeneity of ultra-
sound machines, which provide values that 
are not always comparable, is an important 
limitation of QUS. QUS may be useful 
when lumbar or hip DXA is not feasible, 
and can be recommended for epidemiolog-
ical studies and first line screening, given 
its relatively low cost, portability and lack 
of radiation exposure. Therefore, when 
DXA cannot be performed, a low QUS 
value in conjunction with other clinical risk 
factors for fractures may justify treatment, 
whereas a high QUS value in the absence 
of risk factors suggests a low probability 
of osteoporotic fractures and therefore the 
uselessness of further investigations 
 
Follow up
Assessments of BMD over time may be 
useful both for monitoring the efficacy of 
treatments and to identify subjects who 
are losing bone at a fast rate. The annual 
bone loss in postmenopausal women is 0.5-
2%, and most treatments increase BMD by 
1-6% per year. These changes should be 
compared with the least significant change 
(LSC), i.e., the minimal change detectable 
with the technique used that is not attribut-
able to measurement error. The LSC may 
vary from 2 to 4%, depending on the site 
and technique used, therefore a follow up 
measurement is generally justified after 
1.5-2 years (Table XII), and never earlier 
than 1 year. This time interval may be 
shorter in specific conditions of acceler-
ated bone loss (e.g., high dose glucocor-
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ticoid therapy, malignancy, primary and 
secondary hyperparathyroidism, prolonged 
immobility). Only densitometric measure-
ments performed with the same instrument 
in quality-controlled facilities. 
Densitometric lumbar spine imaging is 
more sensitive to longitudinal changes. As 
such, it should be preferred for monitor-
ing bone mass, provided that concomitant 
conditions that can affect its precision are 
ruled out. Peripheral densitometric mea-
surements (x-ray and ultrasound) are not 
recommended for follow-up, as a substan-
tial period of time is necessary to detect 
significant changes in individual patients. 
Indications for bone mineral density 
testing
Bone densitometry is recommended: i) in 
women aged 65 years and older, and men 
aged 70 years and older; ii) at any age, in 
subjects with previous fragility fractures, x-
ray evidence of osteoporosis or major risk 
factors for osteoporosis (use of drugs asso-
ciated with bone loss, or conditions associ-
ated with osteoporosis); iii) postmenopausal 
women or men older than 60 years with risk 
factors (menopause before 45 years of age, 
or premenopausal amenorrhoea > 6 months, 
inadequate calcium intake or risk factors for 
hypovitaminosis D, prolonged periods of 
immobility, cigarette smoke, alcohol abuse, 
thinness, family history). 
Diagnosis of vertebral fractures
Independent of BMD, a non-traumatic 
vertebral fracture indicates bone fragility. 
If due to osteoporosis, a vertebral fracture 
is a strong indication for pharmacological 
treatment aimed at reducing the risk of fu-
ture fractures. As most vertebral fractures 
are mild in severity and asymptomatic, im-
aging studies are the only way to make a 
diagnosis.
Vertebral fractures are defined according 
to the semiquantitative (SQ) method of 
Genant, as a 20% reduction in height of a 
vertebral body (Figure 1) (74). 
The SQ method is based on a first visual 
inspection of spine images for the differen-
tial diagnosis of vertebral deformities, fol-
lowed by visual grading of the osteoporotic 
vertebral fracture as mild, moderate or se-
vere (Genant criteria). Vertebral morphom-
etry is a quantitative method used for di-
agnosing vertebral fractures by measuring 
vertebral heights. Vertebral morphometry 
should be used to assess the severity of a 
vertebral fracture previously diagnosed by 
the SQ method, and to identify new verte-
bral fractures during follow-up. However, 
vertebral morphometry should always fol-
low a qualitative analysis of spine images 
to rule out causes of deformity other than 
osteoporosis.
Spine images can be acquired via conven-
tional x-ray or DXA, using the Vertebral 
Table XII - Follow up bone mineral density testing not justified earlier than 1 year.
Spine DXA 18 months
Hip DXA 18-24 months
DXA, dual-energy x-ray absorptiometry.
Figure 1 - Definition of vertebral fractures according to the semiquan-
titative method of Genant, as a 20% reduction in height of a vertebral 
body.
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Fracture Assessment (VFA) software pro-
gram that a densitometer may be provided 
with. VFA allows acquiring a radiographic 
image of the entire thoracic and lumbar 
spine, with a low radiation exposure for 
patients (50 µSv, approximately 1/100 of a 
conventional x-ray). After SQ assessment, 
this image is used for vertebral morphom-
etry, i.e., the measurement of the vertebral 
heights. At present, DXA technology deliv-
ers high-resolution images that can be used 
for diagnosing and monitoring osteopo-
rotic vertebral fractures (75-86). However, 
two requirements are necessary for VFA 
to achieve good diagnostic accuracy: i) a 
densitometer delivering images with good 
spatial resolution (≥2 lp/mm); ii) the opera-
tor who interprets the images should have 
adequate experience, documented by certi-
fied specific training, and such to differen-
tiate vertebral fractures from deformities or 
other alterations.
If vertebral fractures caused by conditions 
other than osteoporosis are suspected, VFA 
should be complemented with other con-
ventional radiology techniques or second 
level investigations (CT/MRI) (Table XIII). 
Indications for vertebral fracture testing
Conventional spine x-ray or VFA are indi-
cated:
- in the presence of symptoms suggestive 
for vertebral fracture: intense back pain 
that worsens with standing, current or 
past
- in the absence of symptoms: i) in all 
women aged >70 years and men aged 
>80 years; ii) in all women aged between 
65 and 69 years and in men aged between 
70 and 79 years, if T-score <-1.5; iii) in 
postmenopausal women and men aged 50 
years or older with specific risk factor:
• Previous fragility fractures
• A height loss >4 cm in comparison 
with young age or >2 cm from the last 
visit
• Marked reduction in densitometric 
values (T-score <-3)
• Glucocorticoid therapy with predni-
sone >5 mg per day or equivalent for 
>3 months
• Comorbidities associated with an in-
creased risk of vertebral fractures per se.
Spine magnetic resonance imaging
Use of magnetic resonance imaging (MRI) 
as a diagnostic tool for vertebral fragility 
fractures is indicated when multiple frac-
tures are present. In fact, based on signal 
alterations on STIR- and T2-weighted im-
ages due to bone edema, MRI allows to dif-
ferentiate recent from older fractures, and 
to identify vertebrae free of deformities but 
in which a structural failure is imminent. 
Spine computerized tomography
Computerized tomography allows a de-
tailed evaluation of the bone component of 
a fractured vertebra, providing useful in-
formation, e.g., on the possible dislocation 
of bone fragments into the spinal canal; 
therefore, in selected cases CT is a useful 
investigation that complements MRI. 
BIoCheMICAL dIAGNosIs
An adequate evaluation is particularly recom-
mended in patients with osteoporosis or os-
teopenia more severe than expected for age.
Laboratory testing should be considered 
essential to complete the diagnostic work-
up of osteoporosis, as it: i) may facilitate 
differential diagnosis with other metabolic 
bone diseases that may be associated with 
Table XIII - Sensitivity, specificity and levels of evidence on the clinical use of imaging techniques for 
vertebral fractures.
assessment method sensibility specificity Diagnostic use Follow-up
SQ-Rx +++ +++ A A
SQ-VFA +++ ++- A A
X-ray morphometry +++ +-- B B
VFA	morphometry ++- +-- B B
SQ,	semiquantitative;	VFA,	vertebral	fracture	assessment.
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clinical or densitometric features similar to 
those found in osteoporosis; ii) may identi-
fy potential causative factors, allowing for 
a diagnosis of secondary osteoporosis and, 
whenever possible, an aetiological therapy; 
iii) may guide treatment decisions and help 
assess treatment adherence.
Osteoporosis may be a manifestation of 
several diseases. In 90% of cases, normal 
first tier laboratory results rule out other 
disorders of forms of secondary osteo-
porosis (Grade A recommendation). For 
specific clinical suspicions, more targeted, 
second tier laboratory investigations are 
necessary (Table XIV). 
- The choice of investigations to iden-
tify secondary forms of osteoporosis 
should be based on disease prevalence, 
clinical and drug history, and physical 
examination. 
- Laboratory investigations to rule out 
secondary causes of osteoporosis should 
be prescribed when BMD is below the 
expected range for age (Z-score), or 
whenever satisfactory densitometric re-
sults are not achieved despite adequate 
therapy, in terms of persistence and com-
pliance. 
Biochemical markers of bone turnover
Biochemical markers of bone turnover can 
be measured in serum and/or urine, and are 
classified as markers of bone formation 
(bone-specific alkaline phosphatase, osteo-
calcin, propeptides of type I procollagen) 
and markers of bone resorption (pyridino-
lines, deoxypyridinolines, N- and C- termi-
nal telopeptides of type I collagen).
In adult subjects, an increase in bone 
turnover markers above the normal range 
indicates accelerated bone loss or other 
primary or secondary bone disorders (e.g. 
nutritional osteomalacia, Paget disease, 
bone metastases).
In population studies, particularly in el-
derly postmenopausal women, bone turn-
over markers may be useful in estimating 
fracture risk (Level of evidence 2), even 
regardless of BMD. Bone turnover markers 
are overall indices of bone remodeling, and 
may be useful for assessing the response to 
therapy and treatment adherence.
Table XIV - First and second tier investigations.
First tier investigations
ESR
Complete blood count
Serum protein electrophoresis 
Serum calcium levels
Serum phosphate levels
Total alkaline phosphatase
Serum creatinine
24-h urinary calcium
second tier investigations
Ionized calcium
TSH
PTH
Serum	25-OH-vitamin	D
Cortisol levels after overnight dexamethasone suppression test
Total testosterone in males
Serum or urine immunofixation
Anti-transglutaminase antibodies (+total Ig and with free gluten-containing diet)
Other	specific	investigations	for	associated	diseases	(e.g., ferritin levels, transferrin saturation, tryptase, etc.)
ESR,	erytrocyte	sedimentation	rate;	TSH,	thyroid	stimulating	hormone;	PTH,	parathyroid	hormone.
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In this light, the advantage of using bone 
markers rather than densitometry lies in the 
shorter time needed to evaluate the efficacy 
of antiresorptive or anabolic therapy in the 
individual patient. 
Use of bone markers (for estimating frac-
ture risk and monitoring response to treat-
ment) is complicated by the wide variability 
of dosing methods and biological variabil-
ity, which impacts their use in individual 
patients. Therefore, bone markers cannot be 
used for routine clinical evaluations at pres-
ent; their use should be limited to selected 
cases (e.g., an increase in total alkaline 
phosphatase due to liver disease, evaluation 
of the sustained effect of bisphosphonates 
after treatment discontinuation). 
n	 OSTEOPOROSIS IN MEN 
Osteoporosis in men is also a public health 
burden. Approximately 20% of hip frac-
tures occur in men, and the incidence of 
vertebral fractures in men is approximately 
half of that in women. However, mortality 
and morbidity from spine and hip fractures 
are higher compared with women (87). 
Male osteoporosis is often secondary to 
other causes (approximately 2/3 of cases 
vs 1/3 of cases in women), therefore con-
ditions associated with osteoporosis should 
always be ruled out (88). The most common 
secondary causes in men include hypogo-
nadism, alcohol abuse, multiple myeloma, 
hyperparathyroidism, malabsorption, and 
glucocorticoid use. 
In men with previous fragility fractures, a 
densitometric assessment is needed to con-
firm a diagnosis of osteoporosis. In men 
without fractures, measurement of bone 
mass by DXA is the method of choice for 
defining fracture risk (Level of evidence 1). 
BMD testing by DXA is justified in males 
of any age with a major risk factor (e.g., 
previous fragility fracture, glucocorticoid 
use). BMD testing is also recommended 
in all men between 50 and 69 years of age 
with 2 or more minor risk factors. The main 
risk factors for fracture in men are similar 
to those found in women, i.e., fragility 
fractures, family history of osteoporotic 
fracture, diseases or use of drugs associ-
ated with bone loss. According to the U.S. 
(73) and International Society for Clinical 
Densitometry (71) guidelines, BMD test-
ing by DXA is cost-effective in men older 
than 70 years (Level of evidence 1).
At present, the evidence base of densito-
metric criteria for diagnosing osteoporosis 
in men is not as solid as in women. The 
same diagnostic cut-off as for women is ap-
plied (Level of evidence 2, Grade B recom-
mendation). 
Data on the use of the QUS in men are sim-
ilar to those reported in women, but are not 
conclusive (Level of evidence 2). In men, 
as in women, the use of QUS for monitor-
ing the response to therapy is not recom-
mended (Level of evidence 3) (Table XV). 
A conventional x-ray of the thoracic and 
lumbar spine should be obtained to as-
sess prevalent vertebral deformities in men 
older than 50 years with a history of fragil-
ity fractures, height loss >4 cm compared 
to the height at 20 years of age or gluco-
corticoid therapy (recent or current). An 
x-ray should also be obtained in men aged 
between 70 and 79 years with spine or hip 
T-score is ≤-1.5, and in men older than 80 
years with a T-score ≤-1 (Level of evidence 
2) (71).
Table XV - Levels of evidence for the assessment of fracture risk, diagnosis and follow-up of osteoporosis in men.
site/technique Vertebral fracture risk Non-vertebral  fracture risk Treatment monitoring 
recommendation  
for diagnostic use
Spine BMD/DXA 1a 1a 1b A
Femoral neck BMD/DXA 1a 1a 1b A
Calcaneal BMD DXA 2b 2b ND B
Calcaneal US 1b 1b 3 B
BMD, bone mineral density; DXA, dual-energy x-ray absorptiometry.
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National Osteoporosis Foundation (NOF) 
guidelines (73) recommend initiating phar-
macological therapy in subjects with a 
vertebral (either clinical or morphometric) 
or hip fracture, in those with a diagnosis 
of osteoporosis by DXA (T-score ≤-2.5 at 
the spine or hip) and in men older than 50 
years with a 10-year risk of hip fracture 
≥3% or a 10-year risk of any fracture ≥20% 
using FRAX® in presence of a given value 
of BMD. 
In Italy, two oral (i.e., alendronate and 
risedronate) and one intravenous (i.e. zole-
dronic acid) amonobisphosphonates are 
indicated for the treatment of idiopathic or 
glucocorticoid-induced male osteoporosis 
(Grade A recommendation). Other drugs 
with an indication include denosumab (id-
iopathic male osteoporosis and iatrogenic 
osteoporosis in men with prostate cancer) 
and strontium ranelate. Furthermore, terip-
aratide (20 mcg s.c. per day) has a thera-
peutic indication for severe idiopathic os-
teoporosis in men (as defined by the Note 
79) and in men experiencing a new spine 
or hip fracture during treatment with other 
drugs listed in the Note 79. Drugs with 
proven anti-fracture efficacy in men in-
clude bisphosphonates (alendronate, rise-
dronate, zoledronic acid) and teriparatide 
(38, 89-92). 
Alendronate and risedronate improve bone 
mass at the spine and hip, and reduce ver-
tebral fracture risk in primary male osteo-
porosis and in glucocorticoid-induced os-
teoporosis (Level of evidence 1). There are 
no data on non-vertebral fractures (Level of 
evidence 1). 
Zoledronate was shown to improve verte-
bral and hipbone mass, and to reduce the 
risk of new fractures both in idiopathic male 
osteoporosis and in glucocorticoid-induced 
osteoporosis (Level of evidence 1). 
Denosumab improves BMD in men at high 
risk of fracture (93), and it is indicated 
for the treatment of bone loss in men with 
prostate cancer on androgen deprivation 
therapy (Level of evidence 1). 
Strontium ranelate was shown to increase 
bone mass versus placebo in men (94). 
Teriparatide significantly increases spine 
and hip BMD, and reduces moderate-to-se-
vere vertebral fractures (Level of evidence 
1) (92). Teriparatide for the treatment of 
glucocorticoid-induced osteoporosis ap-
pears to be more effective than alendronate 
or risedronate in increasing BMD and re-
ducing vertebral fractures (Level of evi-
dence 2) (38). There is no evidence of treat-
ments able to reduce non-vertebral fracture 
risk in men. 
The safety profile of these drugs was com-
parable to that reported in postmenopausal 
women with regard to type and incidence of 
adverse events (Level of evidence 1) (95, 96). 
An adequate calcium (1000-1200 mg per 
day) and vitamin D (cholecalciferol 800-
1000 IU per day) intake in combination 
with drug treatment is recommended.
GeNeRAL ReCoMMeNdAtIoNs
- Osteoporosis in men is often secondary 
to other causes, therefore the main con-
ditions/diseases associated with osteo-
porosis should be ruled out
- BMD testing is recommended in men 
with at least one major risk factor or in 
those older than 50 years with at least 
two minor risk factors, or in those older 
than 70 years even in the absence of 
other risk factors for fracture (Grade A 
recommendation). 
- The densitometric threshold for diag-
nosing osteoporosis in men is a T-score 
>-2.5 SD compared to young normal 
adult males (Grade B recommendation) 
- An adequate intake of calcium and vita-
min D should be recommended in con-
junction with drug therapy
- In Italy, drugs with an indication for 
male osteoporosis include alendronate, 
risedronate, zoledronate, denosumab 
and strontium ranelate (Grade A recom-
mendation). Alendronate, risedronate 
and zoledronate have an indication for 
glucocorticoid-induced osteoporosis 
(Grade A recommendation). Teripara-
tide treatment is indicated for severe 
osteoporosis, and in men who experi-
ence a new spine or hip fracture after 1 
year of treatment with other drugs listed 
in the Note 79 (Grade A recommenda-
tion). 
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n	 MANAGEMENT  
 OF OSTEOPOROSIS:  
 NON-PHARMACOLOGICAL  
 INTERVENTIONS
Osteoporosis prevention consists of mea-
sures to prevent or delay the onset of os-
teoporosis. On the other hand, treatment 
of osteoporosis refers to measures to be 
implemented once osteoporosis has been 
diagnosed in subjects with or without 
pre-existing fractures, at increased risk of 
first or new fractures. Prevention is pri-
marily based on risk factor modification. 
Non-pharmacological interventions (diet, 
physical activity, adequate calcium intake 
from diet) or correction of modifiable risk 
factors (cigarette smoke, alcohol abuse, 
environmental risk factors for falls) are 
recommended for all subjects. Non-phar-
macological interventions for prevention 
and treatment are the same. An adequate 
diet, with a correct intake of vitamin D and 
balanced intake of proteins, carbohydrates 
and fats may be useful to achieve optimal 
peak bone mass even at a young age. 
NUtRItIoN 
Calcium intake 
The average daily intake of calcium in the 
Italian population is insufficient, especially 
in the elderly. This dietary deficiency may 
contribute to a negative calcium balance 
and induce secondary hyperparathyroid-
ism, with detrimental consequences.
The recommended dietary allowance of 
calcium varies depending on age and spe-
cific conditions (Table XVI) (73).
It is recommended, whenever possible, to 
increase calcium intake through diet. The 
dose of calcium supplements should be 
selected based on the dietary deficiency 
(in general, however, doses >500-600 mg 
per day are not recommended). Calcium 
supplementation alone was shown able 
to induce modest densitometric improve-
ments in subjects with insufficient intake 
and postmenopausal for more than 5 years. 
A slight reduction in fracture risk, particu-
larly in the elderly, has been reported with 
calcium supplementation has been report-
ed, although not by all. However, the most 
convincing evidence for the anti-fracture 
efficacy is for calcium supplementation in 
conjunction with vitamin D. The efficacy of 
adequate calcium intake is, as for vitamin 
D, proportional to severity and prevalence 
of deficiency in the treated population. 
It should be noted that the risk of kidney 
stones might increase with calcium supple-
mentation, whereas it is reduced by a diet 
rich in calcium. Furthermore, the safety 
profile of calcium supplements has been 
matter of debate due to a potential increase 
in cardiovascular risk. 
Therefore, it is recommended to achieve an 
adequate calcium intake through diet, lim-
iting the use of calcium supplements to sit-
uations where this is not feasible, and only 
until the daily allowance has been achieved 
(Level of evidence 2; Grade A recommen-
dation).
Vitamin D 
The incidence of hypovitaminosis D is 
large in Italy, especially with advancing 
age. It should be noted that only 20% of 
vitamin D needs are met through diet; most 
vitamin D is produced endogenously in the 
Table XVI - Recommended dietary allowance.
Dietary allowance mg per day
1-5 years 800
6-10 years 800-1200
11-24 years 1200-1500
25-50 years 1000
Pregnancy	or	breastfeeding 1200-1500
Postmenopausal	women	on	hormone	replacement	therapy/Men	aged	50-65	years	 1000
Postmenopausal	women	not	on	hormone	replacement	therapy/Men	older	than	65	years	 1200
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skin during exposure to UVB sunrays, al-
though this process becomes less efficient 
with ageing. Therefore, supplementation is 
often needed, particularly in the elderly. In 
conjunction with an adequate calcium in-
take, vitamin D supplementation (cholecal-
ciferol or ergocalciferol, i.e., D
3 
or D
2
) in 
the elderly has been shown useful even for 
primary prevention (Level of evidence 1A; 
Grade A recommendation) (97, 98). 
However, vitamin D supplementation is as-
sociated with modest densitometric effects, 
which are proportional to the severity of vi-
tamin D deficiency and have been reported 
only at the hip. 
The anti-fracture efficacy of vitamin D is 
modest, and has been proven for hip and 
non-vertebral fractures, but not for verte-
bral fractures. The anti-fracture effect ap-
pears to be mediated by the reported reduc-
tion in the risk of falls. 
An adequate calcium and vitamin D in-
take is essential in all pharmacological 
approaches. Calcium and/or vitamin D de-
ficiency is the most common reason for a 
lack of response to pharmacological thera-
py for osteoporosis (99).
A slight but significant reduction in mor-
tality has also been reported with chole-
calciferol or vitamin D
3
 in the elderly, but 
there is no solid evidence for extraskeletal 
benefits, despite a strong pathophysiologi-
cal rationale. 
Daily supplementation with vitamin D is 
the most physiological approach; however, 
it is also reasonable to administer vitamin 
D at equivalent weekly or monthly doses 
in order to improve adherence to treatment. 
When vitamin D is administered at high 
doses (boluses), these should not exceed 
100,000 IU, as increases in bone resorp-
tion markers have been reported with doses 
>100,000 IU (100), and a paradox increase 
in fractures and falls has been reported 
with boluses of 500,000 IU (101).
Vitamin D
3
 should be preferred over D
2
 
to achieve adequate 25(OH)D levels more 
rapidly, limiting the use of the intramuscu-
lar route only to patients with severe mal-
absorption syndromes. 
Adequate comparative evaluations of hy-
droxylated vitamin D metabolites (cal-
cifediol, 1-a calcidiol, calcitiol) at vitamin 
D-equivalent doses are lacking, as well 
as evidence on their anti-fracture efficacy 
comparable to that for cholecalciferol or 
vitamin D
3
. Of note, hydroxylated vitamin 
D metabolites increase the risk of hypercal-
caemia and hypercalciuria, which therefore 
should be ruled out with serial serum and 
urinary calcium measurement. At present, 
the use of hydroxylated vitamin D metab-
olites is rational only in patients with se-
vere liver impairment [25(OH)vitamin D] 
or moderate-to-severe renal impairment, 
1-a-hydroxylase deficiency, severe intes-
tinal malabsorption or hypoparathyroidism 
(hydroxylated metabolites). However, an 
adequate intake of cholecalciferol or D3 
should be ensured even in these situations, 
given the autocrine and paracrine effects, 
as well as the potential extra skeletal ef-
fects of these substances. 
25(OH)vitamin D measurement
Measurement of serum 25(OH)D levels is 
considered the best biochemical indicator 
of vitamin D status (nmol/L = ng/mL x2.5).
Table XVII shows current indications on the 
interpretation of 25(OH)D levels (102-104). 
The risk factors for hypovitaminosis D are 
well known, and the safe therapeutic range 
Table XVII -	Current	indications	on	the	interpretation	of	25(OH)D	levels.
nmol/L ng/mL Interpretation
<25 <10 Severe deficiency
25-50 10-20 Deficiency
50-75 20-30 Insufficiency
75-125 30-50 Ideal range
125-375 50-150 Possible	adverse	events?
>375 >150 Intoxication
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for vitamin D supplementation is wide, 
thanks to the expected physiological mech-
anisms regulating vitamin D hydroxylation. 
Therefore, measurement of serum 25(OH)
D levels, whose cost is considerable, is not 
always justified from a health cost stand-
point, especially in the elderly, as hypo-
vitaminosis D is highly prevalent in this 
population. Neither routine nor screening 
assessments of serum 25(OH)D are recom-
mended, which should be limited to doubt-
ful cases or in the presence of comorbidities 
that increase the risk of severe hypercalcae-
mia (e.g., PHPT, granulomatosis). When 
recommended doses (<4000 IU per day) are 
used, measurement of serum 25(OH) for 
treatment monitoring is not recommended 
either. If deemed appropriate in doubtful 
cases, serum 25(OH)D levels should not 
be measured earlier than 4 months, i.e. the 
amount of time required for 25(OH)D to 
reach the steady state in serum. 
Doses for supplementation
The dose to be used will depend on wheth-
er vitamin D deficiency is to be prevented 
or treated. 
Treatment of vitamin D deficiency  
and insufficiency
The aim of treatment of vitamin D deficien-
cy and insufficiency it to restore 25(OH)
D depots and normal serum levels within 
a short time. The total dose to be adminis-
tered over few weeks may vary, depending 
on the severity of vitamin D deficiency and 
on a patient’s body mass. If deficiency or in-
sufficiency cannot be established by clinical 
evaluation, measurement of serum 25(OH)
D may be considered a good indicator of vi-
tamin D requirements (Table XVIII). 
After correction of 25(OH)D deficiency, 
maintenance therapy should be continued 
in order to avoid recurrence of vitamin D 
deficiency or insufficiency (see prevention). 
The approximate dose indicated in Table 
XVIII should be administered as fractioned 
doses over 1 to 2 months, at daily doses of 
5000-7500 IU or equivalent weekly or bi-
weekly doses. 
Prevention of vitamin D insufficiency
Prevention of vitamin D insufficiency refers 
to the dose of vitamin D to recommend for 
subjects in whom a deficiency has already 
been treated, with the aim of avoiding a 
recurrence. Therefore, once the deficiency 
or insufficiency has been corrected, some-
times using massive initial doses, vitamin 
D supplementation should be continued at 
lower but regular doses over time, taking 
into account the persistence of clinical con-
ditions that are risk factors for vitamin D 
deficiency or insufficiency. 
Table XVIII presents a list of indicative 
criteria. Higher doses may be required in 
patients with poor nutritional status, ad-
vanced age, intestinal malabsorption syn-
dromes, obesity, or taking certain drugs 
(e.g., anticonvulsants or glucocorticoids). 
The present recommendations are based on 
information about the prevalence of vita-
min D deficiency in Italy, and on the fact 
that most guidelines (103, 104), although 
not all (102), consider a level of 30 ng/mL 
as the optimal level to be reached. There-
fore, once the desired vitamin D levels 
have been achieved, even with massive 
initial doses, vitamin D supplementation 
at regular doses should be continued over 
time. 
Other nutrients
Increasing protein intake in subjects with 
inadequate intake reduces hip fracture risk 
in both genders (Level of evidence 3).
Adequate protein intake is essential to 
maintain skeletal and muscle function, but 
also to reduce the risk of complications fol-
lowing an osteoporotic fracture.
Table XVIII -	Estimated	therapeutic	and	maintenance	doses	relative	to	vitamin	D	deficiency	status.
Baseline 25(OH)D level or estimated vitamin D status Total vitamin D dose for treatment Daily maintenance dose
<10 ng/mL or 25 nmol/L 600,000 2000
10-20 ng/mL or 25-50 nmol/L 400,000 1000
20-30 ng/mL or 50-75 nmol/L 100,000 800
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PhYsICAL ACtIVItY
It is known that even short periods of im-
mobility are highly detrimental to bone 
mass. It is therefore important to maintain 
a minimum level of physical activity. 
The role of an exercise program in the pre-
vention of osteoporosis is more uncertain. 
The impact of such programs varies de-
pending on frequency, duration, intensity, 
and age at the beginning of the program. 
Furthermore, the impact is specific for the 
weight-bearing bone site. 
In young women, exaggerated exercise at 
competitive level may lead to hormonal 
and nutritional alterations that may be det-
rimental to bone. 
Types of exercise can be generally clas-
sified into two categories: i) aerobic or 
impact or weight-bearing exercise (e.g., 
running, soccer, basketball, volleyball, 
baseball, racket sports, gymnastics); ii) en-
durance or strength training (weightlifting, 
body building, swimming, cycling, use of 
tools for static exercises).
Studies that assessed the effects of exer-
cise on BMD are mostly case-control, non-
randomized studies, and should be evalu-
ated according to the age of participants. 
In pre-pubertal subjects and young adults, 
only weight-bearing exercises appear to be 
effective (Level of evidence 2A). At pres-
ent, there is insufficient evidence to recom-
mend such exercises for neither primary, or 
secondary prevention. In postmenopausal 
women, weight-bearing exercise may pre-
vent the expected annual bone loss of 1% 
(Level of evidence 1). 
Epidemiological studies on the correlation 
between exercise and lower risk of fracture 
are available. 
Encouraging even modest physical ac-
tivity in the elderly may also contribute 
to reduce the risk of falls and thereby of 
fracture. Despite insufficient evidence on 
the effects on bone mass, the recommen-
dation to perform a minimum amount of 
exercise (walking for more than 30 min-
utes per day, possibly in open air) appears 
reasonable, due to the effect of exercise on 
the risk of falls and on the indirect effect 
on vitamin D levels. 
MeAsURes to RedUCe 
the RIsK oF FALLs
Most fractures, particularly hip fractures, 
are associated with falls. Risk factors for 
falls (motor disability, balance disorders, 
neuromuscular diseases, impaired vision, 
cardiovascular disease, history of falls, 
drugs, cognitive dysfunction) are often 
modifiable in the context of a multidisci-
plinary intervention.
Physical activity, particularly personalized 
exercises to improve muscle strength, bal-
ance and walking, has been shown to reduce 
the risk of both falls (Level of evidence 1) 
and fall-related traumas (Level of evidence 
2A). Fall risk self-assessment tests admin-
istered in conjunction with recommenda-
tions on the prevention of falls also have a 
favorable impact (Level of evidence 2A). 
As an example, a lesser use of psychiatric 
drugs is associated with a reduced risk of 
falls. A fall prevention strategy for the el-
derly including adequate vitamin D intake, 
physical activity and education on home 
risks is highly recommended (Grade A rec-
ommendation). 
PRoteCtoRs
Attenuating the impact force on the bone 
segment by wearing a protector is an alter-
native, or rather complementary strategy to 
reduce the risk of fracture. Protectors have 
been associated with conflicting outcomes, 
therefore their use is recommended only in 
selected cases (very high risk of fall). 
n	 PHARMACOLOGICAL   
 THERAPY 
INteRVeNtIoN thReshoLd
The aim of osteoporosis treatment is to re-
duce fracture risk. Non-pharmacological 
interventions (diet, exercise) or correction 
of modifiable risk factors (cigarette smoke, 
lifestyle) are recommended for all subjects. 
Conversely, a decision to use specific drugs 
is dependent on the risk-benefit assessment. 
This ratio can be easily derived from clini-
cal trials including large groups of patients 
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with similar characteristics, using simple 
parameters such as the Number Needed 
to Treat (NNT) or the Number Needed to 
Harm (NNH), i.e., the number of patients 
who need to be treated to prevent a spe-
cific event or to cause a specific adverse 
event. The issue is more complex for in-
dividual patients. As such, simplifications 
and compromises have been used that are 
generally considered as reasonable. Fur-
thermore, evaluation of treatment appro-
priateness includes aspects of the patient’s 
interest in terms of treatment risk-benefit 
balance, but also social aspects related to 
proper resource use. Therefore, evaluation 
of the appropriateness of pharmacologi-
cal treatment is complex, involving factors 
related to the drug (evidence of efficacy, 
safety data, reliability in terms of feasibil-
ity of treatment and sustained adherence, 
cost) but also to the patient (fracture risk, 
comorbidities, etc.). Specifically, accurate 
fracture risk assessment is as important as 
choosing an effective treatment.
BMD T-scores have been used by the 
WHO to define diagnostic thresholds (os-
teoporosis is defined by a T-score <-2.5), 
and sometimes are used as intervention 
thresholds, e.g. <-2.5 for the U.S. National 
Osteoporosis Foundation (73).
However, use of the diagnostic threshold, 
as a threshold for intervention is not ac-
ceptable. Indeed, fracture risk as defined 
by BMD alone does not take into account 
other important factors that contribute to 
the risk of fracture regardless of BMD, 
e.g., age, glucocorticoid therapy, cigarette 
smoke, thinness, etc., which are generally 
known as clinical risk factors.
Risk factors, such as history of previous os-
teoporotic fractures or glucocorticoid ther-
apy at a daily dose >5 mg prednisone or 
equivalent, are associated with such a high 
risk of fracture that a decision to initiate 
pharmacological therapy may be indepen-
dent of densitometric values. This has been 
recognized by the AIFA Note 79, which 
defines the criteria for drug reimbursement 
in Italy. 
In other situations, the estimate of risk 
and therefore of the intervention thresh-
old should be based on both BMD and 
other clinical risk factors for fracture. An 
integrated assessment of multiple risk fac-
tors, possibly using a mathematical algo-
rithm, can be expressed as lifetime risk or, 
more conveniently, as 10-year fracture risk 
(10YFR). The FRAX® tool is one of the 
most used algorithms, available online at 
https://www.shef.ac.uk/FRAX/. However, 
the FRAX® has intrinsic limitations mainly 
related to the inaccuracy of dichotomous 
variables such as previous fracture, the 
possibility to omit BMD and the exclusion 
of many comorbidities and other important 
variables.
In order to overcome the limitations of the 
FRAX® tool and improve its accuracy, an 
alternative version has been derived from 
FRAX®, i.e., the derived fracture risk as-
sessment or DeFRA® (available online 
at: https://defra-osteoporosi.it/) that pro-
vides a risk estimate essentially similar to 
FRAX®, exclusively based on continuous 
variables (age, BMI, BMD) but more ac-
curate in the evaluation of other clinical 
risk factors, this being more detailed (e.g., 
site and number of previous fractures) and 
complete (e.g., other drugs associated with 
bone loss, other comorbidities, vertebral 
BMD in addition to hip BMD) (105-107). 
The DeFRA® tool allows for a rational 
and consistent diagnostic and therapeu-
tic approach to osteoporosis, specifically 
adapted to the Italian setting and the cri-
teria for treatment decisions defined by the 
AIFA. Furthermore, DeFRA allows strati-
fication of facture risk, which can be used 
for choosing the most appropriate therapy 
in conjunction with criteria such as safety 
(95, 96), cost-effectiveness ratio (108), ex-
pected adherence and pathophysiological 
rationale.
However, it is not advised, at present, to 
make decisions on pharmacological treat-
ment exclusively on the basis of DeFRA® 
scores. DeFRA® should be considered as a 
tool in continuous evolution. In fact, both 
the algorithm and the factorial components 
of the individual clinical risk factors might 
be modified underway, based on data ob-
tained from the DeFRA® itself or from 
new studies or meta-analyses in the scien-
tific literature. 
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BIsPhosPhoNAtes
Bisphosphonates are synthetic compounds 
that selectively bind to bone areas undergo-
ing remodeling. At these sites, bisphospho-
nates inhibit osteoclast activity through a 
mechanism of action that differs depending 
on whether or not they contain an aminic 
group. All bisphosphonates developed so 
far for the treatment of either focal bone 
disorders or osteoporosis reduce bone turn-
over in a dose-dependent manner, with 
proportional increases in bone density. The 
intestinal absorption of bisphosphonates is 
only 0.5-5%. Bisphosphonates currently 
approved for the treatment of osteoporosis 
in Europe include: etidronate, clodronate, 
alendronate, risedronate, ibandronate, and 
zoledronate (72, 73). 
Etidronate and clodronate are non-amino 
bisphosphonates that increase vertebral 
BMD and maintain femoral neck BMD in 
postmenopausal women (Level of evidence 
1). Oral clodronate at a dose of 800 mg per 
day was shown effective in reducing clini-
cal fractures. In Italy, 100 mg per week ad-
ministered via intramuscular (i.m.) route is 
the most commonly used dosage. Assum-
ing an intestinal clodronate absorption of 
2%, the i.m. dosage would be equivalent to 
the oral dose with proven anti-fracture ef-
ficacy. However, studies confirming these 
pharmacokinetic premises by comparing 
the effects of oral and i.m. formulations 
on BMD improvements and bone turnover 
reduction are lacking. The recommended 
and currently used dose of etidronate has 
always been suboptimal in order to avoid 
defective bone mineralization. Etidronate 
and clodronate are therefore considered as 
second-line drugs that are especially used 
in primary prevention, given their low cost. 
Alendronate and risedronate may increase 
vertebral BMD by 10 and 6% over 3 years, 
respectively. Both drugs have high evidence 
of efficacy for the prevention of both verte-
bral and non-vertebral fractures (including 
hip fractures), which are reduced by ap-
proximately 40-50% over 3 years. Anti-
fracture efficacy has been demonstrated for 
daily dosing, and can be assumed for the 
intermittent weekly or monthly regimens, 
based on equivalence of different formula-
tions in inducing an increase in BMD. An 
alendronate oral solution formulation has 
recently become available in Italy. Recent 
data indicate that concomitant use of PPIs 
with oral bisphosphonates may reduce an-
ti-fracture efficacy of the latter (109). 
Ibandronate was approved based on stud-
ies that used the 2.5 mg per day regimen. 
At this dose, ibandronate is only effective 
in reducing vertebral fracture risk. Howev-
er, ibandronate has subsequently been mar-
keted at a dose of 150 mg every month or 3 
mg i.v. every 3 months, i.e., at cumulative-
bioavailable doses twice the dose used in 
registration studies. When compared to the 
oral 2.5 mg per day regimen, this dosage 
was shown able to reduce the risk of non-
vertebral fractures.
Zoledronate (5 mg i.v. every 12 months) 
was approved for the treatment of osteopo-
rosis based on a single study that clearly 
demonstrated an effect on the risk of ver-
tebral, non-vertebral and hip fractures after 
3 years of treatment. The 9-year extension 
study demonstrated that hip bone mass 
remains stable with continued treatment, 
although there were no significant differ-
ences in terms of BMD, bone turnover 
markers and incidence of new fractures as 
compared to the group that discontinued 
treatment after 6 years (110). In an ancil-
lary study, zoledronate reduced the risk of 
new clinical fractures when administered 2 
weeks after a hip fracture. Furthermore, a 
reduction of overall mortality was demon-
strated for the first time with zoledronate.
Alendronate, risedronate and zoledronate 
are also approved for the treatment of os-
teoporosis in men. In a recent controlled 
study, zoledronate significantly reduced the 
risk of morphometric vertebral fractures in 
a large group of men with primary osteopo-
rosis, with or without hypogonadism (111).
Neridronate is the only bisphosphonate 
indicated for the treatment of osteogenesis 
imperfecta. It appears reasonable to assimi-
late any form of juvenile-onset idiopathic 
osteoporosis to osteogenesis imperfecta 
without performing costly and limitedly 
accessible genetic testing. In Italy, neridro-
nate is also indicated for the treatment of 
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algodystrophy (complex regional pain syn-
drome type I), based on data from a recent 
randomized controlled trial (112). 
Safety profile of bisphosphonates 
Overall, bisphosphonates have a favour-
able tolerability profile.
• Gastrointestinal tolerability: oral amino-
bisphosphonates (except for clodronate 
and etidronato) may cause severe oesopha-
geal erosions. The availability of weekly 
and monthly formulations has led to an im-
provement in gastrointestinal tolerability, 
provided that the drug is taken correctly.
• Renal tolerability: bisphosphonates, ei-
ther for oral or intravenous administration, 
are not associated with significant risk for 
renal function. However, adequate fluid 
intake should be ensured with intravenous 
bisphosphonates, and the recommended 
doses and infusion rates should be respect-
ed. If indicated, intravenous bisphospho-
nates may be used even in patients with 
moderate renal impairment, adjusting the 
dose if needed. However, intravenous zole-
dronate is contraindicated in patients with 
glomerular filtration rate less than 35 ml/
min (113). 
• Acute phase reaction: Intravenous admin-
istration of amino-bisphosphonates (but 
also of high-dose oral bisphosphonates) 
may be associated with flu-like clinical 
manifestations of 1-3 days of duration, 
characterized by fever and generalized 
muscle aches and joint pain. Such manifes-
tations are more frequent and severe after 
the first drug administration. Glucocorti-
coid therapy for 2-3 days may be recom-
mended for rare cases when the symptoms 
are more severe and of longer duration. 
• Osteonecrosis of the jaw: in the treatment 
of malignancies (bone metastases, malig-
nant hypercalcaemia, etc.) bisphosphonate 
therapy at doses tens of times greater than 
those used for osteoporosis treatment is as-
sociated with an increased risk (up to 1%) 
of osteonecrosis of the jaw (ONJ). Actual-
ly, it has been revealed to be an osteomyeli-
tis almost invariably associated with an Ac-
tinomyces infection. This adverse effect of 
bisphosphonate therapy is reported much 
less frequently in patients treated for osteo-
porosis, with an increase in risk following 
oral invasive procedures involving bone 
exposure. It is widely accepted that the best 
way of managing ONJ is prevention, which 
is essentially based on risk factor control. 
In patients starting bisphosphonate therapy 
for osteoporosis, a dental examination with 
dental extraction of abscessed or infected 
teeth is not required prior to initiation of 
therapy. Patients should be encouraged to 
maintain routine oral hygiene, similar to 
the general population, especially when 
oral hygiene is insufficient. If invasive 
dental procedures are necessary, initiation 
of therapy may be delayed until resolution 
of the dental problem. Alternatively, pro-
cedures can be performed within the first 
6 months of therapy. In subjects treated 
with bisphosphonates for osteoporosis for 
less than 3 years and without individual 
risk factors (diabetes, immunosuppression, 
glucocorticoids, cigarette smoke, alcohol) 
the risk of ONJ associated with invasive 
procedures is extremely low, and no spe-
cific measures or precautions are required. 
Based on epidemiological data, a dentist’s 
refusal to perform dental procedures, even 
when invasive (dental extractions), or con-
sidering bisphosphonate therapy and the 
dental procedure as mutually exclusive in 
the absence of other documented risk fac-
tors does not appear to be justified. In some 
cases, not performing the procedure could 
be a risk factor for ONJ per se. In subjects 
treated with bisphosphonates for more than 
3 years (with compliance >80%), regular 
professional oral hygiene is recommended, 
in the same manner as in the general popu-
lation. If oral surgery (dental extraction) 
is required, many guidelines recommend 
discontinuation of bisphosphonates for 3 
months and re-initiation of therapy once the 
surgical wound has healed. There is no evi-
dence that this can really reduce the risk of 
ONJ, considering the persistence of effect 
of bisphosphonates. Furthermore, for the 
same reason, it is likely that bisphospho-
nate discontinuation for a relatively short 
period (1-2 months) does not compromise 
the efficacy of treatment for osteoporosis. 
Recently, some authors have proposed 
temporarily suspending treatment follow-
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ing dental extraction, until healing of the 
mucosa at the site of extraction. Prolonged 
interruptions of treatment should be agreed 
upon by the dentist and the physician who 
has prescribed bisphosphonate therapy. In 
the case of invasive dental procedures (den-
tal extraction), especially if individual risk 
factors (diabetes, immunosuppression, glu-
cocorticoids, cigarette smoke, alcohol) are 
present, adequate antibiotic prophylaxis 
(amoxicillin, possibly combined with met-
ronidazole, to be initiated 5 to 2 days prior 
to surgery and to be continued until healing 
of the mucosa) is recommended. Antibiotic 
prophylaxis should be prescribed for surgi-
cal dental extractions that involve primary 
closure of the site of extraction with mo-
bilization of mucoperiosteal flaps. There 
are no contraindications to dental implant 
surgery during bisphosphonate treatment. 
Only 12 cases of ONJ associated with im-
plant surgery are reported in the literature, 
with an estimated risk of implant failure of 
0.88%. However, peri-implantitis, a poten-
tial complication of implant surgery, can 
increase the risk of ONJ during bisphos-
phonate therapy per se. Therefore, it is es-
sential that patients adhere to a strict oral 
hygiene program. The Italian Ministry of 
Health issued recommendations for the 
prevention of ONJ limited to cancer pa-
tients. Recently, a joint document on ONJ 
associated with bisphosphonate use both 
in cancer and osteoporosis was issued by 
the Italian Society of Maxillofacial Surgery 
(SICMF) and the Italian Society of Oral 
Diseases and Medicine (SIPMO) (114). It 
should be noted that many of the recom-
mendations derived from international 
literature and adopted by may guidelines 
have a relatively low level of evidence, but 
a relatively good strength of recommenda-
tion based on expert opinion. 
• Atypical sub-trochanteric fractures: in 
patients treated with bisphosphonates for 
many years (but also in patients never treat-
ed with bisphosphonates), occurrence of 
atypical sub-trochanteric femoral fractures 
(transverse fractures). These are stress frac-
tures that should meet strict classification 
criteria for a diagnosis of atypical fracture 
(115). Incidence of these fractures is very 
low (3.2 to 50 cases per 100,000 person/
year), but clearly associated with duration 
of treatment. Based on available data and 
the rarity of these events, the risk-benefit 
ratio for the use of bisphosphonates in the 
prevention of fragility fractures is clearly 
in favor of a benefit. In order to minimize 
the risk of sub-trochanteric fracture in pa-
tients on bisphosphonate treatment, the 
following may be useful: i) considering 
periods of drug holiday after assessing the 
risk-benefit ratio and ii) correct and moni-
tor other risk factors for atypical fractures 
(long-term glucocorticoid use, hypovita-
minosis D, long-term use of PPIs, bone 
disorders other than osteoporosis). 
For a detailed review of the safety profile 
of bisphosphonate, see the recently pub-
lished SIOMMMS position paper (95) and 
available from the Society’s website (www.
siommms.it).
Duration of therapy
Optimal duration of bisphosphonate therapy 
for osteoporosis has not been established. 
The effects of zoledronate and alendronate 
on BMD and bone turnover persist for few 
months after discontinuation of treatment. 
The need for continued treatment should be 
periodically reassessed in each individual 
patient, taking into consideration benefits 
and potential risks of therapy, especially 
after 5 or more years of use. It appears rea-
sonable to recommend discontinuing treat-
ment for 12-24 month in patients who have 
been treated with bisphosphonates for more 
than 5 years and at low risk of fracture. It 
is recommended to continue treatment up 
to 10 years (maximal duration of treatment 
assessed so far) in patients at high risk of 
fracture, such as those with a hip T-score 
<2.5 or with previous vertebral fractures 
and a hip T-score <-2. 
deNosUMAB
Denosumab is a humanized monoclonal 
antibody that neutralizes RANKL, a cyto-
kine that, by interacting with its receptor 
RANK on the membrane of pre-osteoclasts 
and mature osteoclasts, inhibits osteoclast 
recruitment, maturation and survival. Sub-
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cutaneous administration of denosumab 
leads to nearly complete inhibition of os-
teoclastic bone resorption, and subsequent-
ly of bone formation. As bisphosphonates, 
denosumab is therefore an antiresorptive 
drug. The main differences between these 
drugs are: i) the effect of denosumab ceases 
immediately as the drug is cleared from the 
plasma; therefore, if treatment is interrupt-
ed when a patient is still at increased risk 
of fracture, initiation of an alternative treat-
ment should be considered to prevent rapid 
resumption of bone loss; ii) the consistent 
effect of denosumab at all bone structures, 
regardless of bone turnover, which trans-
lates into a greater pharmacological ac-
tivity at the cortical bone; for this reason, 
increases in BMD are greater as compared 
with the most potent bisphosphonates, par-
ticularly at cortical bone structures; iii) 
long-term denosumab therapy is associated 
with sustained increase in BMD, whereas 
with other anti-resorptive a plateau is seen 
after 3-4 years of treatment, particularly at 
cortical bone structures. 
Registration studies were conducted us-
ing denosumab 60 mg s.c. every 6 months 
(72, 73). This dose ensures nearly complete 
inhibition of bone turnover, although after 
2-4 years this tends to return to pre-treat-
ment levels towards the end of the sixth 
month of the dosing interval. In postmeno-
pausal women, the anti-fracture efficacy of 
denosumab has been documented for ver-
tebral fractures (–68% over 3 years of ther-
apy), hip fractures (–40% over 3 years of 
therapy) and non-vertebral fractures (–20% 
over 3 years of therapy). Denosumab has 
also evidence of efficacy for the treatment 
of men at increased risk of fracture, women 
with breast cancer treated with aromatase 
inhibitors and men on androgen depriva-
tion therapy for prostate cancer. An even 
greater densitometric benefit has been seen 
in patients with severe osteoporosis treated 
with either concomitant teriparatide and 
denosumab therapy or teriparatide follow-
ing denosumab (but not vice versa). 
No significant adverse events were shown 
in clinical trials (95, 96). Denosumab treat-
ment may lead to hypocalcaemia, therefore 
potential risk factors for hypocalcaemia 
should be corrected prior to initiation of 
therapy. In post-registration extension stud-
ies, rare cases of ONJ have been reported. 
This led to considering ONJ pathogenesis 
as related to the reduction in bone turnover. 
For the same reason, use of denosumab 
has been associated, although rarely, with 
atypical femoral fractures (see bisphospho-
nates). A trend for a greater incidence of 
infections, predominantly skin infections, 
was seen during clinical trials. Although 
this was not considered as crucial by the 
European Medicines Agency (EMA) and 
FDA, continued risk assessment through 
the pharmacovigilance program was 
deemed necessary. 
teRIPARAtIde
Daily subcutaneous administration of PTH, 
and specifically of its active 1-34 fragment 
(teriparatide) stimulates both bone forma-
tion and resorption, with a predominant ef-
fect on bone formation (anabolic window) 
that is particularly evident during the first 
12 months of treatment. Observed BMD 
increases are significantly greater than 
those achieved with bisphosphonates only 
in trabecular bone, with an increase in ver-
tebral BMD of nearly 10% at 18 months. 
However, teriparatide treatment also in-
duces improvements in certain geometric 
characteristics of cortical bone that relate 
to its resistance to fracture. 
Teriparatide was shown to reduce (after 21 
months of treatment) vertebral fractures by 
65% and non-vertebral fractures by 53% 
(72, 73). A rapid decrease in BMD is ob-
served at treatment discontinuation. It is 
therefore advisable to promptly initiate an 
alternative (anti-resorptive) treatment. The 
association of teriparatide with other drugs 
has been evaluated in several studies. So 
far, the greatest effect on BMD has been 
achieved with teriparatide in conjunction 
with zoledronate or denosumab. It is be-
lieved that such associations could be con-
sidered for patients at very high risk, such 
as those with multiple vertebral fractures 
or a femoral fracture. The drug is also ap-
proved for the treatment of glucocorticoid-
induced osteoporosis based on a study that 
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demonstrated superior efficacy of teripara-
tide compared to alendronate therapy, both 
with regard to BMD and clinical fractures. 
Due to its high cost, the use of teriparatide 
is limited to secondary prevention in pa-
tients with severe osteoporosis at increased 
risk of fracture or non-responsive to anti-
resorptive drugs. Teriparatide therapy is 
often associated with adverse events of 
mild severity (nausea, cramps in the lower 
limbs) and with increased incidence of hy-
percalcaemia, which is usually asymptom-
atic (95, 96). According to its Summary of 
Product Characteristics, teriparatide treat-
ment should not exceed 24 months and 
should not be repeated over a patient’s life-
time. This limitation poses obvious man-
agement problems. As an example, should 
a patient who discontinues treatment after 
a short period of time for reasons unrelated 
to drug tolerability not be treated for the 
rest of his life? The present guidelines con-
sider the recommendation in the Summary 
of Product Characteristics as referring to a 
total duration of treatment of 24 months, 
with daily administration. 
stRoNtIUM RANeLAte
Treatment with strontium ranelate effec-
tively reduces vertebral, non-vertebral and 
hip fractures in women with postmeno-
pausal osteoporosis. Strontium is the active 
ingredient of the compound, which adsorbs 
to hydroxyapatite crystals with labile bond. 
The mechanism of action of strontium 
ranelate is related to its interaction with 
the calcium sensing receptor (CaSR), and 
involves the OPG-RANKL system. Stron-
tium ranelate was assessed in two 5-year 
clinical trials, involving over 7000 women, 
with the main analysis at 3 years (72, 73). 
Results at 3 years showed that strontium 
ranelate reduced the risk of vertebral, non-
vertebral and hip fractures (in a subgroup 
at high risk) by 41, 16 and 36%, respective-
ly. Results at 5 years confirmed the find-
ings of the first 3 years. Strontium ranelate 
modestly increases markers of bone forma-
tion (approximately by 15%), while reduc-
ing markers of bone resorption (10-15%). 
The greater weight of strontium accounts 
for approximately 50% of the increase in 
BMD observed with treatment. Recently, 
a direct correlation between BMD and the 
reduction in risk for vertebral and hip frac-
tures has been demonstrated. 
Strontium ranelate therapy is associated 
with modest bowel movement pattern 
changes and a mild increase in the risk for 
thromboembolic events, particularly in el-
derly patients: the drug is contraindicated in 
patients with current or past venous throm-
boembolism (VTE) and in the case of tem-
porary or permanent immobilization. Fur-
thermore, the need for continued treatment 
with strontium ranelate should be re-evalu-
ated in patients aged over 80 years at risk 
of VTE. Treatment with strontium ranelate 
was also associated with an increase in the 
risk of myocardial infarction [relative risk 
vs placebo 1.6 (95% CI=1.07; 2.38)] (95, 
96). The drug is therefore contraindicated 
in patients with established, current or past 
history of ischemic heart disease, peripheral 
arterial disease and/or cerebrovascular dis-
ease, and uncontrolled hypertension. 
Severe allergic cutaneous reactions, some-
times associated with potentially life-
threatening systemic symptoms [drug rash 
with eosinophilia and systemic symptoms 
(DRESS), Stevens-Johnson syndrome, 
toxic epidermal necrolysis] have been re-
ported very rarely with strontium ranelate. 
In such cases, treatment should be imme-
diately discontinued, and not re-started 
at any time (EMA/185175/2012). Use of 
strontium ranelate has been restricted to the 
treatment of severe osteoporosis in post-
menopausal women or in adult men at high 
risk of fracture, for whom treatment with 
other medicinal products approved for the 
treatment of osteoporosis is not possible.
hoRMoNe RePLACeMeNt 
theRAPY
Treatment with estrogens, alone or in com-
bination with progestogens (hormone re-
placement therapy, HRT) or tibolone may 
increase bone mass. The Women’s Health 
Initiative (WHI) study demonstrated that 
treatment with conjugated estrogens re-
duces the risk of any osteoporotic fracture. 
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The favorable effect on fracture, which is 
accompanied by a reduction in the risk of 
colorectal cancer, is counterbalanced by 
an increased risk of breast cancer, stroke, 
ischemic heart disease and thromboembol-
ic events, with an unfavorable risk-benefit 
ratio, particularly for long-term treatments 
and when combination therapy with pro-
gestogens is required (women without 
hysterectomy) (72, 73). Based on these 
data, estrogen or combined estrogen/pro-
gestogen therapy is not indicated for the 
treatment or prevention of osteoporosis. In 
women with menopausal symptoms, espe-
cially if aged <50-55 years, temporary (1-3 
years) estrogen or combined estrogen/pro-
gestogen therapy (depending on whether or 
not the patient underwent hysterectomy), 
may be considered as somehow physiolog-
ical and therefore acceptable, also for the 
prevention of osteoporosis. 
seLeCtIVe estRoGeN 
ReCePtoR ModULAtoRs
Selective estrogen receptor modulators 
(SERMs) are synthetic compounds that 
bind the ER thereby inducing agonistic 
effects in bone and liver, and antagonistic 
effects in the mammary gland and genito-
urinary tract. 
SERMs currently approved for the preven-
tion and treatment of osteoporosis in Italy 
include raloxifene and bazedoxifene.
Raloxifene prevents bone loss in the first 
years after menopause, inducing a 2-3% 
increase in bone density in osteoporotic 
women. The anti-fracture efficacy of ral-
oxifene was assessed in a single, large study 
(MORE). After 3 years, raloxifene 60 mg per 
day reduced the incidence of new vertebral 
fractures (but not non-vertebral fractures) in 
both women with previous vertebral frac-
tures (30%) and women with no previous 
fractures (50%). In MORE, a significant re-
duction in the incidence of invasive breast 
cancer was also observed (72, 73). 
Raloxifene does not improve, and may 
even increase the incidence of menopause-
associated vasomotor symptoms. Most 
commonly reported adverse events are in-
creased vasomotor symptoms and cramps 
of the lower limbs. Raloxifene, as HRT, is 
associated with increased risk of thrombo-
embolic events, therefore it is not recom-
mended in patients with previous or at risk 
for venous thrombosis (95, 96). 
Bazedoxifene is a third-generation SERM 
that, at a dose of 20 mg per day, was shown 
to prevent bone loss both in normal and os-
teopenic women. In osteoporotic women, 
bazedoxifene significantly reduced the risk 
of fracture by 42%. The 5-year extension 
study showed persistence of effect on ver-
tebral fractures (32% reduction in risk). 
A post-hoc analysis in patients at high 
risk demonstrated a significant reduction 
in non-vertebral fractures both at 3 and 5 
years (72, 73). Furthermore, bazedoxifene 
showed a greater anti-estrogen effect on 
the uterus, in the absence of significant ad-
verse events (95, 96). A new strategy for 
ER modulation, known as tissue selective 
estrogen complex (TSEC), combines estro-
gen therapy (conjugated equine estrogens) 
with bazedoxifene. Data from clinical trials 
indicate that this association leads to im-
provements of menopausal symptoms and 
bone mass, without causing adverse effects 
on the breast and uterus (116-120). How-
ever, the anti-fracture and cardiovascular 
effects of this association have not been 
adequately investigated yet. 
NeW tReAtMeNt PeRsPeCtIVes
Cathepsin K is a key enzyme for osteo-
clast activity, and it is therefore a potential 
therapeutic target. Odanacatib, a selective 
inhibitor of cathepsin K, was shown able 
to reduce bone resorption by 50%, with-
out affecting bone formation significantly, 
thereby significantly increasing BMD and 
reducing osteoporotic fractures.
Pharmacological inhibition of sclerostin, 
a well-known, natural occurring inhibitor 
of the Wnt system, which is essential for 
bone formation is another potential new 
approach for the treatment of osteoporo-
sis. In fact, administration of sclerostin-
neutralising monoclonal antibodies signifi-
cantly increased BMD and bone strength 
in a relatively short time in preliminary 
experiments. 
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VeRteBRoPLAstY  
ANd KYPhoPLAstY
Vertebral fractures often cause sudden 
and rapidly progressive pain, unrelated to 
traumas, that is initially continuous, also 
present at rest, and subsequently only oc-
curring with load. The management of 
patients with acute vertebral fractures in-
cludes conservative measures such as rest, 
braces or corsets, minor and major analge-
sics. Vertebral fracture pain usually attenu-
ates after 1-3 weeks, and abates over few 
months. However, in many cases pain may 
persist for months, depending on severity 
and fracture site, which impact the clinical 
course and may determine persistent insta-
bility (pseudoarthrosis).
Trans-peduncular injection of cement in 
the fractured vertebral body may induce 
immediate resolution of pain. 
Currently available techniques for stabiliz-
ing or reducing-stabilizing vertebral frac-
tures include vertebroplasty, where cement 
is injected at high pressure, with greater 
risk of extravasation and pulmonary em-
bolism, and kyphoplasty, where cement is 
injected at low pressure, with lower risk of 
extravasation; theoretically, the latter tech-
nique allows reducing vertebral deformity 
by inserting a balloon that is subsequently 
inflated within the vertebral body.
Given the risks and the uncertain long-term 
benefits associated with these procedures, 
vertebroplasty or kyphoplasty should only 
be recommended in patients with intracta-
ble pain lasting for weeks. Both techniques 
should be offered for vertebral fractures 
causing pain for weeks after onset, whereas 
kyphoplasty should be proposed when re-
storing the morphology of a fractured verte-
bral body is deemed feasible, when reduction 
in chest volume may impair a patient’s vital 
capacity, or when there is a risk of a domino 
effect due to biomechanical imbalances.
Of course, using these procedures in patients 
with few or no symptoms is unadvisable. 
Appropriate pharmacological treatment is es-
sential in all patients with vertebral fragility 
fractures treated by vertebroplasty or kypho-
plasty, in order prevent an increase in risk of 
adjacent vertebral fracture associated with 
the presence of cement in a vertebral body in 
a situation of generalized bone fragility.
n	 SYNOPTIC TABLES OF 
 PHARMACOLOGICAL THERAPY
PostMeNoPAUsAL 
osteoPoRosIs 
The pharmacological therapy for post-
menopausal osteoporosis is summarized in 
Tables XIX and XX.
osteoPoRosIs IN MeN
The pharmacological therapy for osteopo-
rosis in men is summarized in Table XXI.
GLUCoCoRtICoId-INdUCed 
osteoPoRosIs
The pharmacological therapy for glucocor-
ticoid-induced osteoporosis is summarized 
in Table XXII.
Acknowledgments: the authors thank Luca 
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Table XIX - Levels of evidence.
Bisphosphonates
Treatment target
BmD Vert Fx Non-vert. Fx Hip Fx
Alendronate 1 1 1 1
Clodronate 800 mg/die/os 1 1 1 -
Etidronato 1 1 - -
Ibandronate 1 1 1* -
Risedronate 1 1 1 1
Zoledronate 1 1 1 1
BMD,	bone	mineral	density.	*Evidence	from	post-hoc studies or meta-analyses (see text).
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Table XX - Levels of evidence.
Other therapies
Treatment target
BmD Vert Fx Non-vert. Fx Hip Fx
Teriparatide 1 1 1 -
PTH	1-84 1 1 - -
Strontium ranelate 1* 1 1 1°
Hormone replacement therapy# 1 1 1 1
Raloxifene 1 1 - -
Bazedoxifene 1 1 - -
Denosumab 1 1 1 1
BMD,	bone	mineral	density;	PTH,	parathyroid	hormone.	*Affected	by	strontium	ranelate’s	higher	molecular	
weight; °evidence from post-hoc studies (see text); #no longer indicated for the treatment of osteoporosis 
due to its adverse effects.
Table XXI - Levels of evidence.
Pharmacological intervention
Treatment target
BmD Vert Fx Non-vert. Fx Hip Fx
Alendronate 1 2 - -
Risedronate 1 2 - -
Zoledronate 1 1 2 2
Teriparatide 1 1 - -
Strontium ranelate 1 - - -
Denosumab 1 1 - -
BMD, bone mineral density.
Table XXII - Levels of evidence.
Pharmacological intervention
Treatment target
BmD Vert Fx Non-vert. Fx Hip Fx
Alendronate 1 1* - -
Risedronate 1 1*° - -
Clodronate 1# 2# - -
Teriparatide 1 1 - -
Zoledronate 1§ - - -
Denosumab 2# - - -
BMD, bone mineral density. *Non primary end-point; °from a meta-analysis of 2 trials; #randomized, open 
label, single centre study, using 100 mg i.m. per week; no specific therapeutic indication in the Summary of 
Product	Characteristics;	§greater densitometric increases compared to risedronate in a head-to-head study.
n	 REFERENCES
1. Hernlund E, Svedbom A, Ivergård M, et al. Osteo-
porosis in the European Union: medical manage-
ment, epidemiology and economic burden. A report 
prepared in collaboration with the International 
Osteoporosis Foundation (IOF) and the European 
Federation of Pharmaceutical Industry Associations 
(EFPIA). Arch Osteoporos. 2013; 8: 136.
2. Kanis JA, Hans D, Cooper C, et al. Interpretation 
and use of FRAX in clinical practice. Osteoporos 
Int. 2011; 22: 2395-411.
3. Morin SN, Lix LM, Leslie WD. The importance 
of previous fracture site on osteoporosis diag-
nosis and incident fractures in women. J Bone 
Miner Res. 2014; 29: 1675-80.
4. Hodsman AB, Leslie WD, Tsang JF, Gamble 
GD. 10-year probability of recurrent fractures 
following wrist and other osteoporotic fractures 
in a large clinical cohort: an analysis from the 
Manitoba Bone Density Program. Arch Intern 
Med. 2008; 168: 2261-7.
5. Gehlbach S, Saag KG, Adachi JD, et al. Previ-
ous fractures at multiple sites increase the risk 
No
n-
co
mm
er
cia
l u
se
 on
ly
guidelines
36 Reumatismo 1/2016
M. Rossini, S. Adami, F. Bertoldo, et al.
for subsequent fractures: The global longitudinal 
study of osteoporosis in women. J Bone Miner 
Res. 2012; 27: 645-53.
6. Kanis JA, Johansson H, Oden A, et al. A family 
history of fracture and fracture risk: a meta-analy-
sis. Bone. 2004; 35: 1029-37.
7. Hippisley-Cox J, Coupland C. Derivation and val-
idation of updated QFracture algorithm to predict 
risk of osteoporotic fracture in primary care in the 
United Kingdom: prospective open cohort study. 
BMJ. 2012; 344: e3427.
8. Vestergaard P. Discrepancies in bone mineral den-
sity and fracture risk in patients with type 1 and 
type 2 diabetes-a meta-analysis. Osteoporos Int. 
2007; 18: 427-44.
9. Janghorbani M, Van Dam RM, Willett WC, Hu 
FB. Systematic review of type 1 and type 2 diabe-
tes mellitus and risk of fracture. Am J Epidemiol 
2007; 166: 495-505.
10. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and 
risk of hip fractures: a meta-analysis. Osteoporos 
Int. 2016; 27: 219-28.
11. van den Bos F, Speelman AD, Samson M, et al. 
Parkinson’s disease and osteoporosis. Age Age-
ing. 2013; 42: 156-62.
12. Dennison EM, Compston JE, Flahive J, et al. Ef-
fect of co-morbidities on fracture risk: findings 
from the global longitudinal study of osteoporosis 
in women (GLOW). Bone. 2012; 50: 1288-93.
13. Broy SB, Tanner SB; FRAX(®) Position Develop-
ment Conference Members. Official positions for 
FRAX® clinical regarding rheumatoid arthritis: 
from joint official positions development confer-
ence of the international society for clinical densi-
tometry and international osteoporosis foundation 
on FRAX®. J Clin Densitom. 2011; 14: 184-9.
14. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident 
fractures in HIV-infected individuals: a systematic 
review and meta-analysis. AIDS. 2013; 27: 1949-
57.
15. Dong HV, Cortés YI, Shiau S, Yin MT. Osteopo-
rosis and fractures in HIV/hepatitis C virus coin-
fection: a systematic review and meta-analysis. 
AIDS 2014; 28: 2119-31.
16. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence 
and prevalence of primary hyperparathyroidism 
in a racially mixed population. J Clin Endocrinol 
Metab. 2013; 98: 1122-9.
17. Fraser WD. Hyperparathyroidism. Lancet. 2009; 
374: 145-58.
18. Bilezikian JP, Brandi ML, Eastell R, et al. Guide-
lines for the management of asymptomatic pri-
mary hyperparathyroidism: summary statement 
from the Fourth International Workshop. J Clin 
Endocrinol Metab. 2014; 99: 3561-9.
19. Gunn IR, Gaffeny D. Clinical and laboratory 
features of calcium-sensing receptor disorders: a 
systematic review. Ann Clin Biochem. 2004; 41: 
441-58.
20. Mollerup CL, Vestergaard P, Frøkjaer VG, et al. 
Risk of renal stone events in primary hyperpara-
thyroidism before and after parathyroid surgery: 
controlled retrospective follow-up study. BMJ. 
2002; 325: 807.
21. Vestergaard P, Mollerup CL, Frøkjaer VG, et al. 
Cohort risk of fracture before and after surgery for 
primary hyperparathyroidism. BMJ. 2000; 321: 
598-602.
22. Canalis E, Mazziotti G, Giustina A, Bilezikian 
JP. Glucocorticoid-induced osteoporosis: patho-
physiology and therapy. Osteoporos Int. 2007; 18: 
1319-28.
23. Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-
induced osteoporosis: mechanisms, management, 
and future perspectives. Lancet Diabetes Endocri-
nol. 2013; 1: 59-70.
24. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled 
corticosteroids for stable chronic obstructive pul-
monary disease. Cochrane Database Syst Rev. 
2012; 7: CD002991.
25. Mattishent K, Thavarajah M, Blanco P, et al. Me-
ta-review: adverse effects of inhaled corticoste-
roids relevant to older patients. Drugs. 2014; 74: 
539-47.
26. Loke YK, Cavallazzi R, Singh S. Risk of fractures 
with inhaled corticosteroids in COPD: system-
atic review and meta-analysis of randomised con-
trolled trials and observational studies. Thorax. 
2011; 66: 699-708.
27. Van Staa TP, Leufkens HG, Cooper C. The epide-
miology of corticosteroid-induced osteoporosis: a 
meta-analysis. Osteoporos Int. 2002; 13: 777-87.
28. Kanis JA, Johansson H, Oden A, et al. A meta-
analysis of prior corticosteroid use and fracture 
risk. J Bone Miner Res. 2004; 19: 893-9.
29. Heffernan MP, Saag KG, Robinson JK, Callen 
JP. Prevention of osteoporosis associated with 
chronic glucocorticoid therapy. JAMA. 2006; 
295: 1300-3.
30. Homik J, Suarez-Almazor ME, Shea B, et al. Cal-
cium and vitamin D for corticosteroid-induced 
osteoporosis. Cochrane Database Syst Rev. 2000; 
(2): CD000952.
31. Laatikainen AK, Kröger HP, Tukiainen HO, et al. 
Bone mineral density in perimenopausal women 
with asthma: a population-based cross-sectional 
study. Am J Respir Crit Care Med. 1999; 159: 
1179-85.
32. Crawford BA, Liu PY, Kean MT, et al. Random-
ized placebo-controlled trial of androgen effects 
on muscle and bone in men requiring long-term 
systemic glucocorticoid treatment. J Clin Endo-
crinol Metab. 2003; 88: 3167-76.
33. Saag KG, Emkey R, Schnitzer TJ, et al. Alendro-
nate for the prevention and treatment of gluco-
corticoid-induced osteoporosis. Glucocorticoid-
Induced Osteoporosis Intervention Study Group. 
N Engl J Med. 1998; 339: 292-9.
34. Reid DM, Hughes RA, Laan RF, et al. Efficacy 
and safety of daily risedronate in the treatment of 
corticosteroid-induced osteoporosis in men and 
women: a randomized trial. European corticoste-
roid-induced osteoporosis treatment study. J Bone 
Miner Res. 2000; 15: 1006-13.
No
n-
co
mm
er
cia
l u
se
 on
ly
Reumatismo 1/2016 37
guidelinesGuidelines for the diagnosis, prevention and management of osteoporosis
35. Reid DM, Devogelaer JP, Saag K, et al. Zole-
dronic acid and risedronate in the prevention and 
treatment of glucocorticoid-induced osteoporosis 
(HORIZON): a multicentre, double-blind, dou-
ble-dummy, randomised controlled trial. Lancet. 
2009; 373: 1253-63.
36. Homik J, Cranney A, Shea B, et al. Bisphospho-
nates for steroid induced osteoporosis. Cochrane 
Database Syst Rev. 2000; (2): CD001347.
37. Rossini M, Orsolini G, Viapiana O, et al. Bisphos-
phonates in the treatment of glucocorticoid-in-
duced osteoporosis: pros. Endocrine. 2015; 49: 
620-7.
38. Saag KG, Zanchetta JR, Devogelaer JP, et al. Ef-
fects of teriparatide versus alendronate for treating 
glucocorticoid-induced osteoporosis: thirty-six-
month results of a randomized, double-blind, con-
trolled trial. Arthritis Rheum. 2009; 60: 3346-55.
39. Dore RK, Cohen SB, Lane NE, et al. Effects of 
denosumab on bone mineral density and bone 
turnover in patients with rheumatoid arthritis 
receiving concurrent glucocorticoids or bisphos-
phonates. Ann Rheum Dis. 2010; 69: 872-5.
40. Nyandege AN, Slattum PW, Harpe SE. Risk of 
fracture and the concomitant use of bisphospho-
nates with osteoporosis-inducing medications. 
Ann Pharmacother. 2015; 49: 437-47. 
41. Cosman F, de Beur SJ, LeBoff MS, et al. Clini-
cian’s guide to prevention and treatment of osteo-
porosis. Osteoporos Int. 2014; 25: 2359-81. 
42. Mazziotti G, Canalis E, Giustina A. Drug-induced 
osteoporosis: mechanisms and clinical implica-
tions. Am J Med. 2010; 123: 877-84. 
43. Kwok CS, Yeong JK, Loke YK. Meta-analysis: 
risk of fractures with acid-suppressing medica-
tion. Bone. 2011; 48: 768-76. 
44. Abrahamsen B, Rubin KH, Eiken PA, et al. Char-
acteristics of patients who suffer major osteopo-
rotic fractures despite adhering to alendronate 
treatment: a National Prescription registry study. 
Osteoporos Int. 2013; 24: 321-8. 
45. Turner MR, Camacho X, Fischer HD, et al. Le-
vothyroxine dose and risk of fractures in older 
adults: nested case-control study. BMJ. 2011; 
342: d2238.
46. Meier C, Kraenzlin ME, Bodmer M, et al. Use of 
thiazolidinediones and fracture risk. Arch Intern 
Med. 2008; 168: 820-5.
47. Miziak B, Blaszczyk B, Chroscinska-Krawczyk 
M, et al. The problem of osteoporostic in epileptic 
patients taking antiepileptic drugs. Expert Opin 
Drug Saf. 2014; 13: 935-46.
48. Krol C, Dekkers M, Kroon M. Longitudinal 
changes in BMD and fracture risk in orthotopic 
liver transplant recipients not using bone-mod-
ifying treatment. J Bone Miner Res. 2014; 29: 
1763-9.
49. Tufano A, Coppola A, Contaldi P, et al. Oral anti-
coagulant drugs and the risk of osteoporosis: new 
anticoagulants better than old? Semin Thromb 
Hemost. 2015; 41: 382-8.
50. Vanderschueren D, Laurent MR, Claessens F, et 
al. Sex steroid actions in male bone. Endocr Rev. 
2014; 35: 906-60. 
51. Shao YH, Moore DF, Shih W, et al. Fracture after 
androgen deprivation therapy among men with a 
high baseline risk of skeletal complications. BJU 
Int. 2013; 111: 745-52. 
52. Hadji P, Gnant M, Body JJ, et al. Cancer treat-
ment-induced bone loss in premenopausal wom-
en: a need for therapeutic intervention? Cancer 
Treat Rev. 2012; 38: 798-806.
53. Kwan ML, Lo JC, Tang L, et al. Bone health his-
tory in breast cancer patients on aromatase inhibi-
tors. PLoS One. 2014; 9: e111477.
54. Zaman K, Thürlimann B, Huober J, et al. Bone 
mineral density in breast cancer patients treated 
with adjuvant letrozole, tamoxifen, or sequences 
of letrozole and tamoxifen in the BIG 1-98 study 
(SAKK 21/07). Ann Oncol. 2012; 23: 1474-81. 
55. Diamond TH, Higano CS, Smith MR, et al. Os-
teoporosis in men with prostate carcinoma receiv-
ing androgen-deprivation therapy: recommenda-
tions for diagnosis and therapies. Cancer. 2004; 
100: 892-9. 
56. Hussain SA, Weston R, Stephenson RN, et al. Im-
mediate dual energy Xray absorptiometry reveals 
a high incidence of osteoporosis in patients with 
advanced prostate cancer before hormonal ma-
nipulation. BJU. 2003; 92: 690-4.
57. Bouvard B, Hoppé E, Soulié P, et al. High preva-
lence of vertebral fractures in women with breast 
cancer starting aromatase inhibitor therapy. Ann 
Oncol. 2012; 23: 1151-6. 
58. Coleman R, Body JJ, Aapro M, et al. Bone health 
in cancer patients: ESMO Clinical Practice 
Guidelines. Ann Oncol. 2014; 25: iii124-37.
59. Rizzoli R, Body JJ, Brandi ML, et al. Cancer-as-
sociated bone disease. Osteoporos Int. 2013; 24: 
2929-53. 
60. Coleman R, de Boer R, Eidtmann H, et al. Zole-
dronic acid (zoledronate) for postmenopausal 
women with early breast cancer receiving adju-
vant letrozole (ZO-FAST study): final 60-month 
results. Ann Oncol. 2013; 24: 398-405.
61. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant 
denosumab in breast cancer (ABCSG-18): a mul-
ticentre, randomised, double-blind, placebo-con-
trolled trial. Lancet. 2015; 386: 433-43.
62. Smith MR, Egerdie B, Hernández Toriz N, et al. 
Denosumab in men receiving androgen-depriva-
tion therapy for prostate cancer. N Engl J Med. 
2009; 361: 745-55. 
63. Greenspan SL, Nelson JB, Trump DL, et al. Skel-
etal health after continuation, withdrawal, or delay 
of alendronate in men with prostate cancer under-
going androgen-deprivation therapy. J Clin Oncol. 
2008; 26: 4426-34.
64. Forbes JF, Cuzick J, Buzdar A, et al. Effect of an-
astrozole and tamixifene as adjuvant treatament 
for early-stage breast cancer: 100-months analysis 
of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
65. Tentori F, McCullough K, Kilpatrick RD, et al. 
High rates of death and hospitalization follow 
No
n-
co
mm
er
cia
l u
se
 on
y
guidelines
38 Reumatismo 1/2016
M. Rossini, S. Adami, F. Bertoldo, et al.
bone fracture among hemodialysis patients. Kid-
ney Int. 2014; 85: 166-73. 
66. Kidney Disease: Improving Global Outcomes 
(KDIGO) CKD-MBD Work Group. KDIGO Clini-
cal Practice Guideline for the Diagnosis, Evalua-
tion, Prevention, and Treatment of Chronic Kidney 
Disease-Mineral and Bone Disorder (CKD-MBD). 
Kidney Int Suppl. 2009; 113: S1-130.
67. Chauhan V, Ranganna KM, Chauhan N, et al. 
Bone disease in organ transplant patients: patho-
genesis and management. Postgrad Med. 2012; 
124: 80-90.
68. Kulak CA, Borba VZ, Kulak J Jr, Custódio MR. 
Osteoporosis after transplantation. Curr Osteopo-
ros Rep. 2012; 10: 48-55.
69. Dalle Carbonare L, Zanatta M, Braga V, et al. 
Densitometric threshold and vertebral fractures 
in heart transplant patients. Transplantation. 2011; 
92: 106-11.
70. Giannini S, Sella S, Silva Netto F, et al. Persis-
tent secondary hyperparathyroidism and vertebral 
fractures in kidney transplantation: role of calci-
um-sensing receptor polymorphisms and vitamin 
D deficiency. J Bone Miner Res. 2010; 25: 841-8.
71. Schousboe JT, Shepherd JA, Bilezikian JP, Baim 
S. Executive summary of the 2013 ISCD position 
development conference on bone densitometry. J 
Clin Densit. 2013; 16: 455-67.
72. Kanis JA, McCloskey EV, Johansson H, et al. Sci-
entific advisory board of the european society for 
clinical and economic aspects of osteoporosis and 
osteoarthritis (ESCEO) and the committee of scien-
tific advisors of the international osteoporosis foun-
dation (IOF). European guidance for the diagnosis 
and management of osteoporosis in postmenopaus-
al women. Osteoporos Int. 2013; 24: 23-57.
73. Cosman F, de Beur SJ, LeBoff MS, et al. Clini-
cian’s guide to prevention and treatment of osteo-
porosis. Osteoporos Int. 2014; 25: 2359-81.
74. Genant HK, Wu CY, van Kuijk C, Nevitt MC. 
Vertebral fracture assessment using a semiquan-
titative technique. J Bone Miner Res. 1993; 8: 
1137-48.
75. Schousboe JT, Debold CR. Reliability and accu-
racy of vertebral fracture assessment with densi-
tometry compared to radiography in clinical prac-
tice. Osteoporos Int. 2006; 17: 281-9.
76. Rossini M, Viapiana O, Idolazzi L, et al. Improve-
ments in the management of rheumatic patients 
from vertebral image obtained through DXA. 
Reumatismo. 2006; 58: 253-60. 
77. Ferrar L, Jiang G, Clowes JA, et al. Comparison 
of densitometric and radiographic vertebral frac-
ture assessment using the algorithm-based quali-
tative (ABQ) method in postmenopausal women 
at low and high risk of fracture. J Bone Miner Res. 
2008; 23: 103-11.
78. Bonnet N, Beneton M, Kanis JA, Charlesworth D. 
Vertebral fracture assessment (VFA) with a densi-
tometer predicts future fractures in elderly women 
unselected for osteoporosis. J Bone Miner Res. 
2008; 23: 1561-8.
79. Fuerst T, Wu C, Genant HK, et al. Evaluation of 
vertebral fracture assessment by dual X-ray ab-
sorptiometry in a multicenter setting. Osteoporos 
Int. 2009; 20: 1199-205.
80. Hospers IC, van der Laan JG, Zeebregts CJ, et al. 
Vertebral fracture assessment in supine position: 
comparison by using conventional semiquantita-
tive radiography and visual radiography. Radiol-
ogy. 2009; 251: 822-8.
81. Buehring B, Krueger D, Checovich M, et al. Ver-
tebral fracture assessment: impact of instrument 
and reader. Osteoporos Int. 2010; 21: 487-94.
82. Jager PL, Jonkman S, Koolhaas W, et al. Com-
bined vertebral fracture assessment and bone 
mineral density measurement: a new standard in 
the diagnosis of osteoporosis in academic popula-
tions. Osteoporos Int. 2011; 22: 1059-68.
83. Diacinti D, Del Fiacco R, Pisani D, et al. Diagnos-
tic performance of vertebral fracture assessment by 
the lunar iDXA scanner compared to conventional 
radiography. Calcif Tissue Int. 2012; 91: 335-42.
84. El Maghraoui A, Rezqi A, Mounach A, et al. Sys-
tematic vertebral fracture assessment in asymp-
tomatic postmenopausal women. Bone. 2013; 52: 
176-80.
85. Diacinti D, Pisani D, D’Avanzo M, et al. Reli-
ability of vertebral fractures assessment (VFA) in 
children with osteogenesis imperfecta. Calcif Tis-
sue Int. 2015; 96: 307-12. 
86. Rosen HN, Vokes TJ, Malabanan AO, et al. The 
official positions of the international society for 
clinical densitometry: vertebral fracture assess-
ment. J Clin Densit. 2013; 16: 482-8.
87. Abrahamsen B, van Staa T, Ariely R, et al. Ex-
cess mortality following hip fracture: a systematic 
epidemiological review. Osteoporos Int. 2009; 20: 
1633-50.
88. Watts NB, Adler RA, Bilezikian JP, et al. Os-
teoporosis in men: an Endocrine Society clini-
cal practice guideline. J Clin Endocrinol Metab. 
2012; 97: 1802-22.
89. Orwoll E, Ettinger M, Weiss S, et al. Alendronate 
for the treatment of osteoporosis in men. N Engl J 
Med. 2000; 343: 604-10.
90. Boonen S, Orwoll ES, Wenderoth D, et al. Once-
weekly risedronate in men with osteoporosis: 
results of a 2-year, placebo-controlled, double-
blind, multicenter study. J Bone Miner Res. 2009; 
24: 719-25.
91. Boonen S, Orwoll E, Magaziner J, et al. Once-
yearly zoledronic acid in older men compared 
with women with recent hip fracture. J Am Geriatr 
Soc. 2011; 59: 2084-90.
92. Orwoll ES, Scheele WH, Paul S, et al. The effect 
of teriparatide [human parathyroid hormone (1-
34)] therapy on bone density in men with osteo-
porosis. J Bone Miner Res. 2003; 18: 9-17.
93. Langdahl BL, Teglbjærg CS, Ho PR, et al. A 
24-month study evaluating the efficacy and safety 
of denosumab for the treatment of men with low 
bone mineral density: results from the ADAMO 
trial. J Clin Endocrinol Metab. 2015; 100: 1335-42. 
No
n-
co
mm
er
ial
 us
e o
nly
Reumatismo 1/2016 39
guidelinesGuidelines for the diagnosis, prevention and management of osteoporosis
94. Kaufman JM, Audran M, Bianchi G, et al. Effi-
cacy and safety of strontium ranelate in the treat-
ment of osteoporosis in men. J Clin Endocrinol 
Metab. 2013; 98: 592-601. 
95. Varenna M, Bertoldo F, Di Monaco M, et al. 
Safety profile of drugs used in the treatment of 
osteoporosis: a systematical review of the litera-
ture. Reumatismo. 2013; 65: 143-66.
96. Rossini M, Adami G, Adami S, et al. Safety is-
sues and adverse reactions with osteoporosis 
management. Expert Opin Drug Saf. 2016; 15: 
321-32.
97. Adami S, Romagnoli E, Carnevale V, et al. 
[Guidelines on prevention and treatment of vi-
tamin D deficiency. Italian Society for Osteopo-
rosis, Mineral Metabolism and Bone Diseases 
(SIOMMMS)]. Reumatismo. 2011; 63: 129-47. 
[Article in Italian]
98. Rossini M, Gatti D, Viapiana O, et al. Vitamin D 
and rheumatic diseases. Reumatismo. 2014; 66: 
153-70.
99. Adami S, Giannini S, Bianchi G, et al. Vita-
min D status and response to treatment in post-
menopausal osteoporosis. Osteoporos Int. 2009; 
20: 239-44.
100. Rossini M, Adami S, Viapiana O, et al. Dose-de-
pendent short-term effects of single high doses 
of oral vitamin D(3) on bone turnover markers. 
Calcif Tissue Int. 2012; 91: 365-9.
101. Sanders KM, Stuart AL, Williamson EJ, et al. 
Annual high-dose oral vitamin D and falls and 
fractures in older women: a randomized con-
trolled trial. JAMA. 2010; 303: 1815-22.
102. Institute of Medicine (US). Committee to review 
dietary reference intakes for vitamin D and cal-
cium. In: Ross AC, Taylor CL, Yaktine AL, Del 
Valle HB, eds. Dietary reference intakes for cal-
cium and vitamin D. Washington, DC: National 
Academies Press; 2011.
103. Holick MF1, Binkley NC, Bischoff-Ferrari HA, 
et al. Guidelines for preventing and treating vi-
tamin D deficiency and insufficiency revisited. J 
Clin Endocrinol Metab. 2012; 97: 1153-8.
104. Rizzoli R, Boonen S, Brandi ML, et al. Vitamin 
D supplementation in elderly or postmenopausal 
women: a 2013 update of the 2008 recommen-
dations from the European Society for Clinical 
and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO). Curr Med Res Opin. 
2013; 29: 305-13.
105. Adami S, Bertoldo F, Brandi ML, et al. [Guide-
lines for the diagnosis, prevention and treatment 
of osteoporosis]. Reumatismo. 2009; 61: 260-
84. [Article in Italian]
106. Adami S, Bianchi G, Brandi ML, et al. Vali-
dation and further development of the WHO 
10-year fracture risk assessment tool in Italian 
postmenopausal women: project rationale and 
description. Clin Exp Rheumatol. 2010; 28: 
561-70.
107. Bonaccorsi G, Fila E, Cervellati C, et al. As-
sessment of fracture risk in a population of 
postmenopausal italian women: a comparison 
of two different tools. Calcif Tissue Int. 2015; 
97: 50-7.
108. Adami S, Bertoldo F, Gatti D, et al. Treatment 
thresholds for osteoporosis and reimbursability 
criteria: perspectives associated with fracture 
risk-assessment tools. Calcif Tissue Int. 2013; 
93: 195-200.
109. Yang SD, Chen Q, Wei HK, et al. Bone fracture 
and interaction between bisphosphonates and 
proton pump inhibitors: a meta-analysis. Int J 
Clin Exper Med. 2015; 8: 4899-910.
110. Black DM, Reid IR, Cauley JA, et al. The ef-
fect of 6 versus 9 years of zoledronic acid treat-
ment in osteoporosis: a randomized second ex-
tension to the Horizon-Pivotal Fracture TRIAL 
(PFT). J Bone Miner Res. 2015; 30: 934-44.
111. Boonen S, Reginster J-Y, Kaufman J-M, et 
al. Fracture risk and zoledronic acid therapy 
in men with Osteoporosis. New Engl J Med. 
2012; 367: 1714-23.
112. Varenna M, Adami S, Rossini M, et al. Treat-
ment of complex regional pain syndrome type I 
with Neridronate: a randomized, double-blind, 
placebo controlled study. Rheumatology (Ox-
ford). 2013; 52: 534-42.
113. Miller PD, Jamal SA, Evenepoel P, et al. Renal 
safety in patients treated with bisphopspho-
nates for osteoporosis: a review. J Bone Miner 
Res. 2013; 28: 2049-59.
114. Bedogni A, Campisi G, Fusco V, Agrillo A. 
Raccomandazioni clinico-terapeutiche su os-
teonecrosi dei mascellari associata a bisfosfo-
nati e sua prevenzione. Padova: CLEUP; 2013.
115. Shane E, Burr D, Abrahamsen B, et al. Atypi-
cal subtrochanteric and diaphyseal femoral 
fractures: second report of a task force of the 
American society for bone and mineral re-
search. J Bone Miner Res. 2014; 29: 1-23.
116. Rossini M, Lello S, Sblendorio I, et al. Profile 
of bazedoxifene/conjugated estrogens for the 
treatment of estrogen deficiency symptoms and 
osteoporosis in women at risk of fracture. Drug 
Des Devel Ther. 2013; 7: 601-10. 
117. Sharifi M, Lewiecki EM. Conjugated estro-
gens combined with bazedoxifene: the first 
approved tissue selective estrogen complex 
therapy. Expert Rev Clin Pharmacol. 2014; 7: 
281-91.
118. Mirkin S, Ryan KA, Chandran AB, Komm BS. 
Bazedoxifene/conjugated estrogens for man-
aging the burden of estrogen deficiency symp-
toms. Maturitas. 2014; 77: 24-31.
119. Valera MC, Gourdy P, Tremollieres F, et al. 
From the Women’s Health Initiative to the 
combination of estrogen and selective ER mod-
ulators to avoid progestin addition. Maturitas. 
2015; 82: 274-7.
120. Pinkerton JV, Harvey JA, Lindsay R, et al. Ef-
fects of bazedoxifene/conjugated estrogens on 
the endometrium and bone: a randomized trial. 
J Clin Endocrinol Metab. 2014; 99: E189-98.
No
n-
co
mm
er
cia
l u
se
 on
ly
